<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NPG//DTD XML Article//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName NPG_XML_Article.dtd?><?SourceDTD.Version 2.7.10?><?ConverterInfo.XSLTName nature2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4495563</article-id><article-id pub-id-type="pii">srep12018</article-id><article-id pub-id-type="doi">10.1038/srep12018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A novel crosstalk between TLR4- and NOD2-mediated signaling in the regulation of intestinal inflammation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hajeong</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Quanju</given-names></name><xref ref-type="aff" rid="a1">1</xref><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Hua</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="a2">2</xref><xref ref-type="aff" rid="a3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Tuo</given-names></name><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Xiaojing</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref><xref ref-type="aff" rid="a2">2</xref></contrib><aff id="a1"><label>1</label><institution>State Key Laboratory of Microbial Metabolism, Sheng Yushou Center of Cell Biology and Immunology and School of Life Sciences &#x00026; Biotechnology, Shanghai Jiao Tong University</institution>, 800 Dongchuan Road, Shanghai, <country>China</country> 200240</aff><aff id="a2"><label>2</label><institution>Department of Microbiology and Immunology, Weill Cornell Medical College</institution>, 1300 York Avenue, New York, NY, <country>USA</country> 10065</aff><aff id="a3"><label>3</label><institution>Department of Breast Surgery, Xiangya Hospital, Central South University</institution>, 87 Xiangya Road, Changsha, Hunan, <country>China</country> 410008</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email>xim2002@sjtu.edu.cn</email> or <email>xim2002@med.cornell.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>07</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>5</volume><elocation-id>12018</elocation-id><history><date date-type="received"><day>02</day><month>04</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>06</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015, Macmillan Publishers Limited</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><p>Although Toll-like receptor 4 (TLR4)- and nucleotide-binding oligomerization domain 2 (NOD2)-mediated signaling mechanisms have been extensively studied individually, the crosstalk between them in the regulation of intestinal mucosal defense and tissue homeostasis has been underappreciated. Here, we uncover some novel activities of NOD2 by gene expression profiling revealing the global nature of the cross-regulation between TLR4- and NOD2-mediated signaling. Specifically, NOD2 is able to sense the intensity of TLR4-mediated signaling, resulting in either synergistic stimulation of Interluekin-12 (IL-12) production when the TLR signaling intensity is low; or in the inhibition of IL-12 synthesis and maintenance of intestinal mucosal homeostasis when the TLR signaling intensifies. This balancing act is mediated through receptor-interacting serine/threonine kinase 2, and the transcriptional regulator CCAAT/enhancer-binding protein &#x003b1; (C/EBP&#x003b1;) via its serine 248 phosphorylation by Protein Kinase C. Mice deficient in C/EBP&#x003b1; in the hematopoietic compartment are highly susceptible to chemically induced experimental colitis in an IL-12-dependent manner. Additionally, in contrast to the dogma, we find that the major Crohn&#x02019;s disease-associated NOD2 mutations could cause a primarily immunodeficient phenotype by selectively impairing TLR4-mediated IL-12 production and host defense. To restore the impaired homeostasis would be a way forward to developing novel therapeutic strategies for inflammatory bowel diseases.</p></abstract></article-meta></front><body><p>Inflammatory bowel disease (IBD), particularly Crohn&#x02019;s disease (CD), involves the interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in both innate and adaptive immune systems<xref ref-type="bibr" rid="b1">1</xref>. CD has a strong genetic basis<xref ref-type="bibr" rid="b2">2</xref><xref ref-type="bibr" rid="b3">3</xref>. Nucleotide-binding oligomerization domain 2 (NOD2) is an important regulator in the broad context of host resistance to microbial challenge as well as maintenance of tissue homeostasis. The gene encoding NOD2, <italic>CARD15</italic>, is the first susceptibility gene discovered for CD<xref ref-type="bibr" rid="b2">2</xref><xref ref-type="bibr" rid="b3">3</xref>. Three main variants of NOD2 have been identified: R702W, G908R, and 1007fs, which together represent ~80% of the total NOD2 mutations independently associated with susceptibility to CD<xref ref-type="bibr" rid="b4">4</xref><xref ref-type="bibr" rid="b5">5</xref>. How these human NOD2 mutants contribute to the development and pathogenesis of CD has been quite controversial, reflecting the complexity of the physio-biological properties of NOD2<xref ref-type="bibr" rid="b6">6</xref><xref ref-type="bibr" rid="b7">7</xref><xref ref-type="bibr" rid="b8">8</xref><xref ref-type="bibr" rid="b9">9</xref>.</p><p>Although there is documented evidence for a synergism between TLR2/4- and NOD2-mediated signaling in cytokine production<xref ref-type="bibr" rid="b10">10</xref><xref ref-type="bibr" rid="b11">11</xref><xref ref-type="bibr" rid="b12">12</xref>, NOD2 is able to inhibit TLR2/4-mediated induction of inflammatory cytokine production and induce immune tolerance and homeostasis<xref ref-type="bibr" rid="b7">7</xref><xref ref-type="bibr" rid="b13">13</xref><xref ref-type="bibr" rid="b14">14</xref>. Yet, the mechanisms whereby NOD2 confers these activities, particularly in immune cells, remain highly murky. In mice, Watanabe <italic>et al.</italic> showed that intact NOD2 signaling inhibited TLR2-driven activation of NF-&#x003ba;B, principally, c-Rel<xref ref-type="bibr" rid="b7">7</xref>. NOD2 deficiency or the presence of a CD-like mutation in NOD2 increased TLR2-mediated activation of c-Rel, and Th1 responses were enhanced<xref ref-type="bibr" rid="b7">7</xref>.</p><p>The critical roles of IL-12 and IL-23 in human CD pathogenesis have been strongly implicated in human clinical studies demonstrating that CD but not ulcerative colitis is associated with high levels of both IL-12 and IL-23 secretion<xref ref-type="bibr" rid="b15">15</xref><xref ref-type="bibr" rid="b16">16</xref>, and blocking p40 by monoclonal antibodies is therapeutically beneficial<xref ref-type="bibr" rid="b17">17</xref><xref ref-type="bibr" rid="b18">18</xref>. However, because IL-23 shares the p40 subunit with IL-12, the role of IL-12 had not been precisely determined in early studies using neutralizing p40 Abs. Becker <italic>et al.</italic> demonstrated that IL-23p19-deficient mice were highly susceptible to the development of trinitrobenzene sulfonic acid (TNBS)-induced colitis and exhibited more severe colitis than wild type (WT) mice. Further analyses revealed that dendritic cells (DCs) from p19-deficient mice produced elevated levels of IL-12, and that IL-23 down-regulated IL-12 expression upon TLR ligation. Additionally, <italic>in vivo</italic> blockade of IL-12p40 in IL-23-deficient mice rescued mice from lethal colitis. This study clearly reveals a cross-regulation of IL-12 expression by IL-23 as a key regulatory pathway during initiation of T cell dependent colitis<xref ref-type="bibr" rid="b19">19</xref>. Strober <italic>et al.</italic> showed that NOD2 activation by its ligand muramyl dipeptide (MDP), a conserved motif present in peptidylglycan (PGN) from both Gram-positive and Gram-negative bacteria<xref ref-type="bibr" rid="b20">20</xref><xref ref-type="bibr" rid="b21">21</xref>, could downregulate responses to TLR stimulation, and thus murine cells lacking NOD2 mount increased responses to such stimulation<xref ref-type="bibr" rid="b22">22</xref>. Therefore, interactions between NOD2 and specific TLR pathways represent important but understudied modulatory mechanisms of innate and adaptive responses, particularly in the context of intestinal inflammatory diseases. The current study was undertaken to further investigate this novel but overlooked aspect of immunoregulation at multiple mechanistic levels.</p><sec disp-level="1" sec-type="results"><title>Results</title><sec disp-level="2"><title>NOD2-mediated signaling interacts with TLR4-mediated signaling</title><p>To assess the role of NOD2 in TLR4-mediated production of important cytokines, we derived bone marrow macrophages (BMDMs) from WT and NOD2-knockout (KO) mice, stimulated them with LPS with or without MDP, followed by analyzing expressed cytokine mRNA and secreted protein levels. As shown in <xref ref-type="fig" rid="f1">Fig. 1a</xref> (mRNA) and <bold>b</bold> (protein), NOD2 deficiency strongly reduced LPS-induced levels of IL-12p40 (shared subunit by IL-12 and IL-23), IL-12p70 and TNF-&#x003b1;, but not that of IL-10. MDP by itself didn&#x02019;t induce detectable levels of these cytokines. The combination of LPS and MDP reduced the level of p35 mRNA, and accordingly the level of IL-12 in a selective manner because none of the other cytokines were affected by the MDP treatment. These data suggest that endogenous NOD2 is required for LPS-induced production of inflammatory cytokines in an MDP-independent manner. In contrast, when activated by MDP, NOD2 acts as a selective inhibitor of IL-12p35 gene transcription, illustrating the crosstalk between TLR4- and MDP-induced signaling that leads to a highly selective control of IL-12 production.</p><p>For a more comprehensive understanding of the interaction between NOD2- and TLR4-mediated signaling, we performed whole exon NexGen RNA sequencing of macrophages from WT and NOD2 KO mice treated with LPS alone or with both LPS and MDP together. Clustering analysis of the sequencing data involving 17484 genes (<xref ref-type="fig" rid="f2">Fig. 2</xref>) shows that in WT macrophages, MDP and LPS stimulated different sets of genes (compare Groups 5 and 1 against Group 6). MDP treatment inhibited many of a gene induced by LPS while also stimulated the expression of numerous others (compare Group 2 against Group 1). Strikingly, in the absence of NOD2, macrophages were spontaneously and broadly activated, which were strongly suppressed by LPS treatment (compare Group 3 to Group 8), again demonstrating a mutually restrictive relationship between the two signaling pathways.</p><p>More detailed analyses revealed that with LPS alone, only one gene was differentially upregulated more than 6-fold in mRNA expression in LPS-activated WT macrophages over NOD2-deficient cells: growth differentiation factor 15 (GDF15) (<xref ref-type="table" rid="t1">Table 1</xref>). Under the condition of MDP and LPS, only five genes were differentially upregulated more than 6-fold compared to NOD2-deficient cells, including also GDF15 (<xref ref-type="table" rid="t2">Table 2</xref>). In contrast, under both of these conditions in the absence of NOD2, large numbers of genes were upregulated, many dramatically. These &#x0201c;asymmetric&#x0201d; expression patterns suggest that NOD2 signaling primarily functions to limit, rather than to augment, LPS-induced inflammatory activities.</p></sec><sec disp-level="2"><title>NOD2-and TLR4-mediated signaling mutually antagonizes on IL-12p35 gene transcription</title><p>To further characterize the selective targeting of the interaction between TLR4- and NOD2-signaling on IL-12 gene expression at the transcriptional level, we used a well-established reporter system in which the human IL12p35 gene promoter from &#x02212;1082 to +61 linked to the firefly luciferase gene<xref ref-type="bibr" rid="b23">23</xref> was transiently transfected into the mouse macrophage cell line RAW264.7. We analyzed the transcription of IL-12p35 promoter-luciferase reporter gene under these conditions. As shown in <xref ref-type="fig" rid="f3">Fig. 3a</xref>, LPS induced p35 transcriptional activity was inhibited by MDP in a dose-dependent manner. Reciprocally, MDP enhanced p35 promoter activity at low doses of LPS (1&#x02013;50&#x02009;ng/ml), whereas it inhibited the transcription at the high dose (1&#x02009;&#x003bc;g/ml) (<xref ref-type="fig" rid="f3">Fig. 3b</xref>). The selective inhibition of MDP on high doses of LPS-induced transcription of the p35 but not p40 gene was corroborated on the endogenous counterparts in primary human monocytes (<xref ref-type="fig" rid="f3">Fig. 3c</xref>). Thus, NOD2 signaling can &#x0201c;sense&#x0201d; the intensity of TLR4-induced cellular activation, and plays a dual role in the production of IL-12.</p></sec><sec disp-level="2"><title>NOD2-mediated regulation of IL-12 expression is RIP2-dependent and NF-&#x003ba;B-independent</title><p>To further delineate the molecular mechanisms underlying NOD2-mediated selective inhibition of IL-12p35 gene transcription, we analyzed macrophages derived from mice deficient in receptor interacting protein 2 (RIP2)<xref ref-type="bibr" rid="b24">24</xref>, the protein kinase downstream of NOD2. We observed that in mice genetically deficient in RIP2, the inhibition of IL-12p35 mRNA expression by MDP in LPS-activated, highly inflammatory peritoneal macrophages was completely lost (<xref ref-type="fig" rid="f4">Fig. 4a</xref>, upper panel, white bars), in comparison to the lack of responses of the p40 (mid-panel) and TNF-&#x003b1; (lower panel) genes in the same cells. The RIP2 dependency is consistent with the previous observation by Biswas <italic>et al.</italic> that RIP2- and NOD2-deficient mice share the same susceptibility to <italic>Helicobacter hepaticus</italic>-induced granulomatous inflammation of the ileum, characterized by an increased expression of Th1-related genes and inflammatory cytokines<xref ref-type="bibr" rid="b25">25</xref>.</p><p>In contrast, in mice deficient in c-Rel, the most vital component of the NF-&#x003ba;B complex for IL-12p35 transcription<xref ref-type="bibr" rid="b26">26</xref>, the relative degree of inhibition by MDP was intact in activated macrophages (<xref ref-type="fig" rid="f4">Fig. 4a</xref>, upper panel, gray bars), although the absolute levels of p35 transcription were severely reduced. The responses of IL-12 and IL-23 protein secretion were very similar to those of the individual cytokine chains at mRNA levels (<xref ref-type="fig" rid="f4">Fig. 4b</xref>). The NF-&#x003ba;B independency was corroborated by treating THP-1 cells (a human macrophage cell line) with a well-known and highly specific inhibitor of I&#x003ba;B&#x003b1; phosphorylation, Bay11&#x02013;7082<xref ref-type="bibr" rid="b27">27</xref>, which at the low dose of 0.5&#x02009;&#x003bc;M resulted in a partial inhibition of IL-12p35 mRNA synthesis (<xref ref-type="fig" rid="f4">Fig. 4c</xref>), while having little impact on the relative degrees to which MDP inhibited p35 mRNA levels in activated cells without (black bars) or with (gray bars) the inhibitor.</p></sec><sec disp-level="2"><title>NOD2-and LPS-mediated regulation of IL-12p35 transcription via a proximal promoter element</title><p>To further explore the transcriptional mechanism whereby MDP through activation NOD2 regulates IL-12p35 gene expression, a series of 5&#x02032; and 3&#x02032; deletion constructs of the IL-12p35 promoter were tested to localize the <italic>cis</italic>-element, named &#x0201c;NOD2 Response Element&#x0201d; (N2RE), which mediated MDP-induced inhibition of p35 transcription. The systematic search led to a small region between &#x02212;39 and &#x02212;29 upstream of the transcription initiation site of the p35 promoter with the sequence <underline>TATAAAAATGTGGC</underline> (<xref ref-type="fig" rid="f5">Fig. 5a</xref>). Base-substitutions with this region in reporter constructs b and c resulted in a dramatic loss of the transcriptional activity, presumably due to the disruption of the critically important TATA box<xref ref-type="bibr" rid="b28">28</xref>. Changes in constructs d, e, and f, however, resulted in elevated basal transcription levels while the LPS-stimulated transcriptional activity was not reduced compared to the wild type construct, and almost complete loss of the promoter&#x02019;s response to MDP-induced inhibition.</p><p>An in silico analysis of the 14-bp NRE sequence critical for the MDP response using the transcriptional factor site prediction algorithm, Matlnspector<sup>TM</sup> (Genomatix, Germany), unveiled a link between a member of the CCAAT/enhancer-binding protein (C/EBP) transcription factor family, C/EBP&#x003b1;, and the basal transcription machinery at the TATA box. C/EBP&#x003b1; is a key regulator of myeloid differentiation<xref ref-type="bibr" rid="b29">29</xref><xref ref-type="bibr" rid="b30">30</xref>. It is critical for early granulocytic differentiation via induction of granulocyte-specific genes<xref ref-type="bibr" rid="b31">31</xref><xref ref-type="bibr" rid="b32">32</xref>. Loss of CEBP&#x003b1; function in myeloid cells <italic>in vitro</italic> and <italic>in vivo</italic> leads to a differentiation block, similar to that observed in blasts from acute myeloid leukemia (AML) patients<xref ref-type="bibr" rid="b33">33</xref><xref ref-type="bibr" rid="b34">34</xref>. Nerlov <italic>et al.</italic> found that the three C/EBP&#x003b1; transactivation elements (TEs) synergistically activate transcription in mammalian cells; and two of these elements, TE-I and -II, co-operatively mediate <italic>in vitro</italic> binding of C/EBP&#x003b1; to TATA-box binding protein (TBP) and transcription factor IIB (TFIIB), two essential components of the RNA polymerase II basal transcriptional apparatus<xref ref-type="bibr" rid="b35">35</xref>.</p><p>By chromatin immunoprecipitation (ChIP) assay, we confirmed the physical interaction of C/EBP&#x003b1; with this IL-12p35 promoter element in bone marrow derived murine macrophages. As shown in <xref ref-type="fig" rid="f5">Fig. 5b</xref>, C/EBP&#x003b1; binding was constitutively present and was increased significantly following dual treatment with LPS and MDP, but not by either agent alone, consistent with the functional outcome.</p></sec><sec disp-level="2"><title>Hematopoietic C/EBP&#x003b1; is essential in MDP-induced inhibition of IL-12 production</title><p>To determine whether C/EBP&#x003b1; was critical to MDP-inhibition of IL-12 production, we isolated BMDMs from WT and conditional C/EBP&#x003b1; KO mice. Mx1-Cre transgene expression can be induced by administration of polyinosinic-polycytidylic acid [poly (I:C)], leading to deletion of the floxed <italic>cebpa</italic> gene in the hematopoietic compartment, as we described previously<xref ref-type="bibr" rid="b36">36</xref>. The BMDMs were stimulated with LPS with or without MDP, followed by cytokine measurements by ELISA. As shown in <xref ref-type="fig" rid="f6">Fig. 6a</xref>, loss of C/EBP&#x003b1; did not affect LPS-induced IL-12p70, p40, and TNF-&#x003b1; production but caused a specific reversal of the inhibition of IL-12p70 production by MDP, confirming the essentiality of C/EBP&#x003b1; in this pathway.</p><p>Posttranslational modifications of C/EBP&#x003b1;, such as phosphorylation at different serine/threonine residues, have been found to be an important mechanism of regulating its transcriptional activity<xref ref-type="bibr" rid="b37">37</xref><xref ref-type="bibr" rid="b38">38</xref>. We investigated the functionality of the phosphorylation of C/EBP&#x003b1; using different serine/threonine phosphorylation mutants of C/EBP&#x003b1;<xref ref-type="bibr" rid="b36">36</xref> cotransfected with the IL-12p35 luciferase reporter into RAW264.7 cells. As shown in <xref ref-type="fig" rid="f6">Fig. 6b</xref>, among the four established C/EBP&#x003b1; mutants tested, only the S248A mutant of C/EBP&#x003b1; completely lost its inhibitory activity against p35 transcription whereas the other three mutants retained full repressive activity. Since protein kinase K (PKC) has been implicated in the phosphorylation of S248 in Ras-mediated signaling and activation of C/EBP&#x003b1; in granulocytic differentiation<xref ref-type="bibr" rid="b39">39</xref>, we sought to determine the role of PKC and S248 in the activity of C/EBP&#x003b1; using a potent pan-PKC inhibitor, staurosporine. The inhibition of PKC resulted dose-dependently but partially in the enhancement of the p35 transcriptional suppression caused by the overexpression of C/EBP&#x003b1; (<xref ref-type="fig" rid="f6">Fig. 6c</xref>).</p><p>Taken together, the data clearly demonstrate that (1) C/EBP&#x003b1; is a physiological mediator of MDP-induced inhibition of p35 expression and IL-12 production in inflammatory macrophages; (2) C/EBP&#x003b1;&#x02019;s activity is critically dependent on serine 248 of C/EBP&#x003b1;; (3) PKC activities are required for MDP to regulate p35 transcription in LPS activated macrophages; (4) C/EBP&#x003b1; acts in this pathway directly by binding to the p35 gene promoter at the N2RE, blocking its transcription.</p></sec><sec disp-level="2"><title>Hematopoietic C/EBP&#x003b1; mediates MDP&#x02019;s protection against experimental colitis</title><p>To determine definitively whether MDP&#x02019;s rescuing effects on TNBS-induced colitis<xref ref-type="bibr" rid="b13">13</xref> were dependent on C/EBP&#x003b1;, we used the conditional C/EBP&#x003b1;-deficient mice in which hematopoietic cell-specific deletion of the <italic>cebpa</italic> gene is initiated by the administration of poly I-C<xref ref-type="bibr" rid="b36">36</xref>. As shown in <xref ref-type="fig" rid="f7">Fig. 7a</xref>, compared to WT mice, C/EBP&#x003b1;-deficient mice were more susceptible to colitis-associated weight loss. They also displayed more severe colonic tissue inflammation induced by TNBS administration (<xref ref-type="fig" rid="f7">Fig. 7d,e</xref>). Crucially, MDP&#x02019;s ability to protect mice from TNBS-induced colitis was completely lost in C/EBP&#x003b1;-deficient mice (<xref ref-type="fig" rid="f7">Fig. 7a</xref>). Further, we tested the effect of neutralizing antibodies against IL-12 and IL-23, respectively. Compared with the control IgG-treated mice, colitis was completely rescued by the IL-12-neutralizing antibody in WT and C/EBP&#x003b1;-deficient mice (<xref ref-type="fig" rid="f7">Fig. 7b</xref>) but not by anti-IL-23 (<xref ref-type="fig" rid="f7">Fig. 7c</xref>), consistently with the degrees of serum levels of IL-12 (<xref ref-type="fig" rid="f7">Fig. 7f</xref>).</p><p>Together, these data demonstrate that loss of hematopoietic C/EBP&#x003b1; renders greater susceptibility to TNBS-induced colitis; IL-12 is the primary target in the MDP/NOD2-C/EBP&#x003b1; regulatory axis; MDP requires C/EBP&#x003b1; to selectively inhibit IL-12 production and to resist TNBS-induced pathogenesis.</p></sec><sec disp-level="2"><title>1007fs acts as a &#x0201c;dominant negative&#x0201d; against NOD2</title><p>To further investigate the molecular mechanisms whereby the NOD2 mutations may impact on IL-12 gene expression we expressed recombinant NOD2 and the three major CD-associated mutants: 1007fs, R702W, and G908R. These mutants were expressed at mRNA and protein levels almost as efficiently as the WT NOD2 (<xref ref-type="fig" rid="f8">Fig. 8a</xref>). In contrast to the enhancing activity of the low-dose NOD2, the three mutants inhibited p35 transcription in the absence of MDP (<xref ref-type="fig" rid="f8">Fig. 8b</xref>, upper), but not p40 (middle), nor IL-10 (lower). Thus, it appears that the NOD2 mutants have an &#x0201c;acquired activity&#x0201d; selectively inhibiting p35 gene transcription in a MDP-independent manner.</p><p>To determine if NOD2 and 1007fs could functionally compete (for example, in a heterozygous person) we cotransfected NOD2 and 1007fs together at various molar ratios into RAW264.7 cells, together with the IL12p35 promoter-luciferase reporter. When 1007fs became more abundant than NOD2, it countered the stimulatory effect of NOD2 on p35 transcription (<xref ref-type="fig" rid="f8">Fig. 8c</xref>). Since we have previously demonstrated that NOD2 and 1007fs could physically associate with one another<xref ref-type="bibr" rid="b6">6</xref>, it is very likely that 1007fs&#x02019; IL-12p35-inhibiting activity was the result from its &#x0201c;dominant negative&#x0201d; (DN) activity against NOD2 via physical association with each other.</p><p>These results are also largely consistent with a report that human DCs derived from CD patients bearing heterologous 1007fs mutation, when infected <italic>in vitro</italic> with the Gram-negative bacteria <italic>Salmonella typhimurium</italic>, were severely deficient in IL-12 production<xref ref-type="bibr" rid="b40">40</xref>. Our own analysis of three homozygous 1007fs-CD patients also revealed severely impaired IFN-&#x003b3; production by their PBMCs stimulated <italic>in vitro</italic> with intact <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="fig" rid="f8">Fig. 8d</xref>), which implies an underlying defect in the production of IL-12, the most important inducer of IFN-&#x003b3; production by activated T and NK cells.</p></sec></sec><sec disp-level="1" sec-type="discussion"><title>Discussion</title><p>A number of novel and potentially important findings have been obtained from this work. We have uncovered an unappreciated regulatory crosstalk between the TLR4- and NOD2-mediated signaling pathways of NOD2, being able to regulate the expression of a large number of genes by LPS-activated macrophages. The comprehensive RNAseq analyses of the global gene expression comparisons between WT and NOD2-deficient macrophages have clearly revealed the cross-regulatory nature of the TLR4- and NOD2-mediated signaling in macrophage activation. The probing also specifically identified GDF-15 as the most downregulated gene in the absence of NOD2. GDF15 is a member of the TGF-&#x003b2; superfamily<xref ref-type="bibr" rid="b41">41</xref>, which is widely distributed in mammalian tissues and has been shown to play multiple roles in various pathologies, including inflammation, cancer, cardiovascular diseases, and obesity<xref ref-type="bibr" rid="b42">42</xref>. GDF-15 serum levels are a highly reliable predictor of disease progression. However, the biological significance underlying these observations is far from clear. GDF15 could have a positive or negative role depending on the state of cells or their environment<xref ref-type="bibr" rid="b43">43</xref>. We speculate that GDF15 may be a crucial anti-inflammatory factor limiting macrophage activation in a NOD2-dependent manner. It is noteworthy that the majority of the large numbers of genes strongly upregulated in the absence of NOD2 represent proteolytic enzymes and peptidases involved in inflammation, suggesting that the principle way by which NOD2 limits tissue damages by activated macrophages is to control the production of these enzymes during inflammatory responses.</p><p>Further, we have identified hematopoietically derived C/EBP&#x003b1; as a critical balancing regulator between host defense and inflammation. This crosstalk results in balanced regulation of IL-12 production depending on the inflammatory intensities of the cell. To our knowledge, this is the first study demonstrating a potential role of C/EBP&#x003b1; in CD. Previously, genome-wide association studies have identified protein tyrosine phosphatase, non-receptor type 2 (PTPN2) as susceptibility gene for IBD<xref ref-type="bibr" rid="b44">44</xref><xref ref-type="bibr" rid="b45">45</xref><xref ref-type="bibr" rid="b46">46</xref>. Interestingly, a recent in silico analysis revealed that the CD-associated <italic>PTPN2</italic> SNP rs7234029 modulates potentially the binding sites of several transcription factors involved in inflammation including GATA-3, NF-&#x003ba;B, C/EBP, and E4BP4<xref ref-type="bibr" rid="b47">47</xref>.</p><p>TNBS colitis exhibits heightened Th1-Th17 response (increased IFN-&#x003b3; and IL-17) as the disease becomes chronic, similarly to human CD<xref ref-type="bibr" rid="b6">6</xref><xref ref-type="bibr" rid="b48">48</xref><xref ref-type="bibr" rid="b49">49</xref><xref ref-type="bibr" rid="b50">50</xref>. Our data here lends support to the notion that overexpression of IL-12, not IL-23, is responsible for exacerbated intestinal inflammation in the acute disease model as a result of the loss of hematopoietic C/EBP&#x003b1;-mediated regulation. It should be noted that a study by Biswas <italic>et al.</italic> in NOD2-deficient mice inoculated with <italic>Helicobacter hepaticus</italic> indicated that non-hematopoietic NOD2 may play a more important role in this model<xref ref-type="bibr" rid="b51">51</xref>. This finding exemplifies the complex and controversial nature of studies of NOD2&#x02019;s broad biological activities in the regulation of host defense mechanisms and intestinal inflammation that involve the use of many different models focusing on various aspects and anatomic locations of the disease, genetic background, housing conditions, and disease triggers.</p><p>Thirdly, we further elucidated how the CD-associated human mutations in NOD2, 1007fs in particular, may act as &#x0201c;dominant negatives&#x0201d; to counter the normal activities of NOD2. These mutants, by virtue of their inability to bind MDP, lose the activity to induce NF-&#x003ba;B, thus the production of inflammatory cytokines and host responses to invading pathogens (&#x0201c;loss of function&#x0201d;). What we have uncovered in this study is a &#x0201c;gain of function&#x0201d; activity of these mutants to selectively inhibit LPS-induced IL-12 production in an MDP-independent manner by acting as &#x0201c;dominant negatives&#x0201d; against NOD2 via physical association with each other. This finding provides a better explanation than the current dogmas for how the disease develops in patients bearing these mutations, a highly controversial issue that has been dogging the field of CD research for years. Our results are largely consistent with the report that human DCs derived from CD patients bearing heterologous 1007fs mutation, when infected <italic>in vitro</italic> with the Gram-negative bacteria <italic>Salmonella typhimurium</italic>, were severely deficient in IL-12 production<xref ref-type="bibr" rid="b40">40</xref>. This notion is also supported experimentally by a study of Morosky <italic>et al.</italic> showing that NOD2 negatively regulates type I interferon induction by retinoid acid-induced gene-I (RIG-I) in inflammatory signaling, and that the three main NOD2 mutants form an interaction with RIG-I and negatively regulate its signaling to a greater extent than WT NOD2<xref ref-type="bibr" rid="b52">52</xref>. The &#x0201c;dominant negative&#x0201d; role of 1007fs has also been observed in cells infected with human cytomegalovirus in which virus-induced NOD2 signaling initiates innate immune responses and restricts virus replication<xref ref-type="bibr" rid="b53">53</xref>.</p><p>A significant implication of the observed &#x0201c;acquired&#x0201d; and &#x0201c;intrinsic&#x0201d; activity of 1007fs to inhibit IL-12 production selectively is that in 1007fs-heterozygous patients, the mutation may lead to diminished host defense against pathogens when the activating signal MDP is not present, whereas its inability to respond to MDP (&#x0201c;loss of function&#x0201d;) would result in exacerbated inflammation in the face of mixed infectious agents producing both LPS and MDP. In CD patients carrying NOD2 mutations on the other hand, a principally immunodeficient phenotype is predicted and supported by clinical observations that humoral or cellular immune defects caused by impaired cytokine production can predispose to exacerbated intestinal mucosal inflammation<xref ref-type="bibr" rid="b54">54</xref>. The immunodeficiency theory further hypothesizes that defects in innate immunity leading to compensatory immune processes underlie the CD phenotype and suggests that therapy should stimulate immunity rather than suppress it<xref ref-type="bibr" rid="b55">55</xref>. Indeed, therapeutic approaches such as the clinical use of antibiotic therapy or granulocyte macrophage colony stimulating factor are consistent with the concept of an immunodeficiency being a crucial element in CD.</p><p>In summary, our study demonstrates that the signaling pathways of TLR4 and NOD2 can mutually regulate one another in inflammatory cells. NOD2 signaling activated by MDP, in a RIP2-dependent manner, induces the phosphorylation of C/EBP&#x003b1; via PKC at serine 248. Activated C/EBP&#x003b1; then binds to the IL-12p35 promoter at the &#x0201c;AAAAATGTGG&#x0201d; sequence between &#x02013;31 and &#x02013;22, blocking its transcriptional initiation. The precise role of RIP2 in this pathway remains to be further elucidated. Modulation of IL-12 production serves to maintain intestinal immune balance and tissue homeostasis via an elaborate network of players. Disturbance in the crosstalk between these two pathways, such as those caused by the disease-associated NOD2 mutations, may shift the homeostatic balance in a microbial context-dependent manner. To restore the impaired homeostasis would be a way forward to developing novel therapeutic strategies.</p></sec><sec disp-level="1" sec-type="methods"><title>Methods</title><sec disp-level="2"><title>Cells</title><p>The murine macrophage-like cell line, RAW264.7, was obtained from American Type Culture Collection (Manassas, VA) and maintained in RPMI1640 containing 10% FBS, 2&#x02009;mM L-glutamine, and penicillin/streptomycin. Bone marrow derived macrophages were isolated from mice and induced the differentiation for 7 day in DMEM containing 10% FBS, 20% L929 conditioned medium and penicillin/streptomycin. Medium was changed twice a week during maintaining.</p></sec><sec disp-level="2"><title>Reagents and Plasmids</title><p>Recombinant murine and human IFN-&#x003b3; were purchased from R&#x00026;D system. LPS from <italic>E. coli</italic> 0127:B8 was from Sigma-Aldrich. Bay11&#x02013;7082 was kindly provided by Dr. E. Cesarman of Weill Cornell Medical College, staurosporine was from Calbiochem (Madison, WI). The wild type (WT) C/EBP&#x003b1; expression vector and its mutant (S21A, T222A/T226A, S193A, and S248A) expression vectors were generously provided by Dr. MacDougald (University of Michigan Medical School, Ann Arbor, MI). The human Nod2 expression vector and the 3020insC Nod2 mutant were generated by overlapping PCR, were reported previous our report<xref ref-type="bibr" rid="b6">6</xref>. Anti-mouse IL-12 antibody (C17.8), and its control antibody was from BioXcell. Anti-mouse IL-23 (G23-8) and its control antibody were from eBioscience.</p></sec><sec disp-level="2"><title>Mice</title><p>Nod2-knockout (KO), C/EBP&#x003b1;-conditional KO and control mice were purchased from The Jackson Laboratories (Bar Harbor, ME). C/EBP&#x003b1;-conditional KO mice were homozygous for C/EBP&#x003b1; floxed allele and hemizygous for the Mx1-Cre transgene. To induce Mx1-Cre gene expression, 3 weeks old mice were injected i.p. with 250&#x02009;&#x003bc;g of polyinosinic-polycytidylic acid [poly(I:C)] (Sigma Aldrich, St. Louis, MO), every other day for 2 weeks as we previously reported<xref ref-type="bibr" rid="b36">36</xref>. All animal procedures were conducted in accordance with the institutional IACUC&#x02019;s approved guidelines of Shanghai Jiaotong University and Weill Cornell Medical College.</p></sec><sec disp-level="2"><title>Induction of colitis</title><p>Conditional deletion of C/EBP&#x003b1; using poly I-C was performed as we described previously<xref ref-type="bibr" rid="b36">36</xref>. For colitis induction, TNBS (3.5 mg) in 100&#x02009;&#x003bc;l of 45% ethanol was injected intrarectally into mice on day 0. MDP (100&#x02009;&#x003bc;g) or PBS was injected on days &#x02013;3, &#x02013;2, and &#x02013;1 via i.p., relative to TNBS injection. Neutralizing antibodies (250&#x02009;&#x003bc;g) were injected i.p. on days 0 and 2.</p></sec><sec disp-level="2"><title>Histological analysis</title><p>Colon tissues were harvested on day 4. They were stained with H&#x00026;E and analyzed for inflammation scores on a scale of 1&#x02013;5, as described by Watanabe <italic>et al.</italic><xref ref-type="bibr" rid="b13">13</xref>. Histology was scored as follows: 0, no sign of inflammation; 1, very low level; 2, low level of leukocytic infiltration; 3, high level of leukocytic infiltration, high vascular density, and thickening of the colon wall; and 4, transmural infiltrations, loss of goblet cells, high vascular density, and thickening of the colon wall.</p></sec><sec disp-level="2"><title>Electroporation and luciferase assay</title><p>Transient transfection in RAW264.7 cells was performed by electroporation as previously described (ref). Amaxa Cell Line Nuclerofector Kit V was used for transient transfection in THP1 cells as following manufacture&#x02019;s protocol. Luciferase assay was performed as previously described<xref ref-type="bibr" rid="b23">23</xref>.</p></sec><sec disp-level="2"><title>Cytokine assays</title><p>mIL-12p40, mIL-12p70, mIL-10, and mTNF-a cytokine secretion was measured by the respective ELISA kits from BD Pharmingen (San Diego, CA). Mouse IL-23 was measured by an ELISA kit from Biolegend (San Diego, CA). All experiments were performed three times independently.</p></sec><sec disp-level="2"><title>Quantitative real-time PCR</title><p>mRNA were isolated using the RNeasy mini kit (Qiagen, Hilden, Germany) and reverse-transcribed into cDNA. Real-time PCR was performed with an AB17400 System using the SYBR GREEN PCR kit (Applied Bioscience). The following primers were used for PCR amplification: 1) mouse IL-12/IL-23p40, 5&#x02032;-GGAAGCACGGCAGCAGAATAAAT-3&#x02032;, 5&#x02032;-AACTTGAGGGAGAAGTAGGAATGG- 3&#x02032;, 2) mouse IL-12p35, 5&#x02032;-CCCTTGCCCTCCTAAACCAC, 5&#x02032;-TAGTAGCCAGGCAACTCTCG-3&#x02032;.</p></sec><sec disp-level="2"><title>Chromatin-immunoprecipitation assays (ChIP)</title><p>ChIP assay was performed as previously described<xref ref-type="bibr" rid="b23">23</xref>. The primers in the mouse IL-12p35 promoters: 5&#x02032;-CACAGTCCTGGGAAAGTCCT &#x02212;3&#x02032;, 5&#x02032;-CGGCCCTCAGGTACTTACAG -3&#x02032;.</p></sec><sec disp-level="2"><title>RNA sequencing and data analysis</title><p>Total RNA was isolated from mouse bone marrow macrophages using the RNeasy mini kit (Qiagen) according to manufacturer&#x02019;s instructions. The quantity and quality of total RNA were checked by Nanodrop 8000 (Thermo Scientific) and Bioanalyzer 2100 (Agilent). Sequencing libraries for whole transcriptome analysis were generated following illumine TruSeq RNA low sample preparation protocol. Libraries were quantified by using a 2100 BioAnalyzer(Agilent) and Qubit Fluorometer 2.0 (invitrogen). Nine pM denatured libraries were loaded on an illumine HiSeq 2500 instrument using single read clustering and 51 cycles sequencing (per lane). Program Tophat was used to align the sequenced reads to the UCSC mm9 mouse reference genome, and program Cufflinks was used to measure transcript abundances in reads per kilobase of exon model per million mapped reads (RPKM).</p><p>The authors confirm that all animal experimental protocols were approved by the IACUC committee of Shanghai Jiaotong University (SJTU), and all <italic>in vitro</italic> experiments adhered to the biosafety standards approved by the Environmental Health and Safety Committee of SJTU.</p></sec></sec><sec disp-level="1"><title>Additional Information</title><p><bold>How to cite this article</bold>: Kim, H. <italic>et al.</italic> A novel crosstalk between TLR4- and NOD2-mediated signaling in the regulation of intestinal inflammation. <italic>Sci. Rep.</italic><bold>5</bold>, 12018; doi: 10.1038/srep12018 (2015).</p></sec><sec sec-type="supplementary-material" id="S1"><title>Supplementary Material</title><supplementary-material id="d33e27" content-type="local-data"><caption><title>Supplementary information
</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-s1.pdf"/></supplementary-material></sec></body><back><ack><p>This project was supported in part by a grant from the Natural Science Foundation of China (31370903) to X.M.</p></ack><ref-list><ref id="b1"><mixed-citation publication-type="journal"><name><surname>Arseneau</surname><given-names>K. O.</given-names></name>, <name><surname>Tamagawa</surname><given-names>H.</given-names></name>, <name><surname>Pizarro</surname><given-names>T. T.</given-names></name> &#x00026; <name><surname>Cominelli</surname><given-names>F.</given-names></name>
<article-title>Innate and adaptive immune responses related to IBD pathogenesis</article-title>. <source>Curr Gastroenterol Rep</source>
<volume>9</volume>, <fpage>508</fpage>&#x02013;<lpage>512</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">18377804</pub-id></mixed-citation></ref><ref id="b2"><mixed-citation publication-type="journal"><name><surname>Ogura</surname><given-names>Y.</given-names></name>
<italic>et al.</italic>
<article-title>A frameshift mutation in NOD2 associated with susceptibility to Crohn&#x02019;s disease</article-title>. <source>Nature</source>
<volume>411</volume>, <fpage>603</fpage>&#x02013;<lpage>606</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11385577</pub-id></mixed-citation></ref><ref id="b3"><mixed-citation publication-type="journal"><name><surname>Hugot</surname><given-names>J. P.</given-names></name>
<italic>et al.</italic>
<article-title>Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn&#x02019;s disease</article-title>. <source>Nature</source>
<volume>411</volume>, <fpage>599</fpage>&#x02013;<lpage>603</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11385576</pub-id></mixed-citation></ref><ref id="b4"><mixed-citation publication-type="journal"><name><surname>Lesage</surname><given-names>S.</given-names></name>
<italic>et al.</italic>
<article-title>CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease</article-title>. <source>Am J Hum Genet</source>
<volume>70</volume>, <fpage>845</fpage>&#x02013;<lpage>857</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11875755</pub-id></mixed-citation></ref><ref id="b5"><mixed-citation publication-type="journal"><name><surname>Hugot</surname><given-names>J. P.</given-names></name>
<italic>et al.</italic>
<article-title>Prevalence of CARD15/NOD2 mutations in Caucasian healthy people</article-title>. <source>Am J Gastroenterol</source>
<volume>102</volume>, <fpage>1259</fpage>&#x02013;<lpage>1267</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17319929</pub-id></mixed-citation></ref><ref id="b6"><mixed-citation publication-type="journal"><name><surname>Noguchi</surname><given-names>E.</given-names></name>, <name><surname>Homma</surname><given-names>Y.</given-names></name>, <name><surname>Kang</surname><given-names>X.</given-names></name>, <name><surname>Netea</surname><given-names>M. G.</given-names></name> &#x00026; <name><surname>Ma</surname><given-names>X.</given-names></name>
<article-title>A Crohn&#x02019;s disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1</article-title>. <source>Nat Immunol</source>
<volume>10</volume>, <fpage>471</fpage>&#x02013;<lpage>479</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19349988</pub-id></mixed-citation></ref><ref id="b7"><mixed-citation publication-type="journal"><name><surname>Watanabe</surname><given-names>T.</given-names></name>, <name><surname>Kitani</surname><given-names>A.</given-names></name>, <name><surname>Murray</surname><given-names>P. J.</given-names></name> &#x00026; <name><surname>Strober</surname><given-names>W.</given-names></name>
<article-title>NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses</article-title>. <source>Nat Immunol</source>
<volume>5</volume>, <fpage>800</fpage>&#x02013;<lpage>808</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15220916</pub-id></mixed-citation></ref><ref id="b8"><mixed-citation publication-type="journal"><name><surname>Kobayashi</surname><given-names>K. S.</given-names></name>
<italic>et al.</italic>
<article-title>Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract</article-title>. <source>Science</source>
<volume>307</volume>, <fpage>731</fpage>&#x02013;<lpage>734</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15692051</pub-id></mixed-citation></ref><ref id="b9"><mixed-citation publication-type="journal"><name><surname>Maeda</surname><given-names>S.</given-names></name>
<italic>et al.</italic>
<article-title>Nod2 mutation in Crohn&#x02019;s disease potentiates NF-kappaB activity and IL-1beta processing</article-title>. <source>Science</source>
<volume>307</volume>, <fpage>734</fpage>&#x02013;<lpage>738</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15692052</pub-id></mixed-citation></ref><ref id="b10"><mixed-citation publication-type="journal"><name><surname>Fritz</surname><given-names>J. H.</given-names></name>
<italic>et al.</italic>
<article-title>Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists</article-title>. <source>European journal of immunology</source>
<volume>35</volume>, <fpage>2459</fpage>&#x02013;<lpage>2470</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16021602</pub-id></mixed-citation></ref><ref id="b11"><mixed-citation publication-type="journal"><name><surname>Tada</surname><given-names>H.</given-names></name>, <name><surname>Aiba</surname><given-names>S.</given-names></name>, <name><surname>Shibata</surname><given-names>K.</given-names></name>, <name><surname>Ohteki</surname><given-names>T.</given-names></name> &#x00026; <name><surname>Takada</surname><given-names>H.</given-names></name>
<article-title>Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells</article-title>. <source>Infection and immunity</source>
<volume>73</volume>, <fpage>7967</fpage>&#x02013;<lpage>7976</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16299289</pub-id></mixed-citation></ref><ref id="b12"><mixed-citation publication-type="journal"><name><surname>Netea</surname><given-names>M. G.</given-names></name>
<italic>et al.</italic>
<article-title>Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release</article-title>. <source>J Immunol</source>
<volume>174</volume>, <fpage>6518</fpage>&#x02013;<lpage>6523</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15879155</pub-id></mixed-citation></ref><ref id="b13"><mixed-citation publication-type="journal"><name><surname>Watanabe</surname><given-names>T.</given-names></name>
<italic>et al.</italic>
<article-title>Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis</article-title>. <source>J Clin Invest</source>
<volume>118</volume>, <fpage>545</fpage>&#x02013;<lpage>559</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18188453</pub-id></mixed-citation></ref><ref id="b14"><mixed-citation publication-type="journal"><name><surname>Watanabe</surname><given-names>T.</given-names></name>
<italic>et al.</italic>
<article-title>Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis</article-title>. <source>Immunity</source>
<volume>25</volume>, <fpage>473</fpage>&#x02013;<lpage>485</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16949315</pub-id></mixed-citation></ref><ref id="b15"><mixed-citation publication-type="journal"><name><surname>Monteleone</surname><given-names>G.</given-names></name>
<italic>et al.</italic>
<article-title>Interleukin 12 is expressed and actively released by Crohn&#x02019;s disease intestinal lamina propria mononuclear cells</article-title>. <source>Gastroenterology</source>
<volume>112</volume>, <fpage>1169</fpage>&#x02013;<lpage>1178</lpage> (<year>1997</year>).<pub-id pub-id-type="pmid">9098000</pub-id></mixed-citation></ref><ref id="b16"><mixed-citation publication-type="journal"><name><surname>Schmidt</surname><given-names>C.</given-names></name>
<italic>et al.</italic>
<article-title>Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn&#x02019;s disease but not in ulcerative colitis</article-title>. <source>Inflamm Bowel Dis</source>
<volume>11</volume>, <fpage>16</fpage>&#x02013;<lpage>23</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15674109</pub-id></mixed-citation></ref><ref id="b17"><mixed-citation publication-type="journal"><name><surname>Mannon</surname><given-names>P. J.</given-names></name>
<italic>et al.</italic>
<article-title>Anti-interleukin-12 antibody for active Crohn&#x02019;s disease</article-title>. <source>N Engl J Med</source>
<volume>351</volume>, <fpage>2069</fpage>&#x02013;<lpage>2079</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15537905</pub-id></mixed-citation></ref><ref id="b18"><mixed-citation publication-type="journal"><name><surname>Sandborn</surname><given-names>W. J.</given-names></name>
<italic>et al.</italic>
<article-title>A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn&#x02019;s disease</article-title>. <source>Gastroenterology</source>
<volume>135</volume>, <fpage>1130</fpage>&#x02013;<lpage>1141</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18706417</pub-id></mixed-citation></ref><ref id="b19"><mixed-citation publication-type="journal"><name><surname>Becker</surname><given-names>C.</given-names></name>
<italic>et al.</italic>
<article-title>Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis</article-title>. <source>J Immunol</source>
<volume>177</volume>, <fpage>2760</fpage>&#x02013;<lpage>2764</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16920909</pub-id></mixed-citation></ref><ref id="b20"><mixed-citation publication-type="journal"><name><surname>Girardin</surname><given-names>S. E.</given-names></name>
<italic>et al.</italic>
<article-title>Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection</article-title>. <source>J Biol Chem</source>
<volume>278</volume>, <fpage>8869</fpage>&#x02013;<lpage>8872</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12527755</pub-id></mixed-citation></ref><ref id="b21"><mixed-citation publication-type="journal"><name><surname>Inohara</surname><given-names>N.</given-names></name>
<italic>et al.</italic>
<article-title>Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn&#x02019;s disease</article-title>. <source>J Biol Chem</source>
<volume>278</volume>, <fpage>5509</fpage>&#x02013;<lpage>5512</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12514169</pub-id></mixed-citation></ref><ref id="b22"><mixed-citation publication-type="journal"><name><surname>Strober</surname><given-names>W.</given-names></name>, <name><surname>Kitani</surname><given-names>A.</given-names></name>, <name><surname>Fuss</surname><given-names>I.</given-names></name>, <name><surname>Asano</surname><given-names>N.</given-names></name> &#x00026; <name><surname>Watanabe</surname><given-names>T.</given-names></name>
<article-title>The molecular basis of NOD2 susceptibility mutations in Crohn&#x02019;s disease</article-title>. <source>Mucosal Immunol</source>
<volume>1 Suppl 1</volume>, <fpage>S5</fpage>&#x02013;<lpage>9</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">19079230</pub-id></mixed-citation></ref><ref id="b23"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>J.</given-names></name>, <name><surname>Cao</surname><given-names>S.</given-names></name>, <name><surname>Herman</surname><given-names>L. M.</given-names></name> &#x00026; <name><surname>Ma</surname><given-names>X.</given-names></name>
<article-title>Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1</article-title>. <source>J Exp Med</source>
<volume>198</volume>, <fpage>1265</fpage>&#x02013;<lpage>1276</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">14568984</pub-id></mixed-citation></ref><ref id="b24"><mixed-citation publication-type="journal"><name><surname>Kobayashi</surname><given-names>K.</given-names></name>
<italic>et al.</italic>
<article-title>RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems</article-title>. <source>Nature</source>
<volume>416</volume>, <fpage>194</fpage>&#x02013;<lpage>199</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11894098</pub-id></mixed-citation></ref><ref id="b25"><mixed-citation publication-type="journal"><name><surname>Holler</surname><given-names>E.</given-names></name>
<italic>et al.</italic>
<article-title>The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation</article-title>. <source>Int J Immunogenet</source>
<volume>35</volume>, <fpage>381</fpage>&#x02013;<lpage>384</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18976442</pub-id></mixed-citation></ref><ref id="b26"><mixed-citation publication-type="journal"><name><surname>Grumont</surname><given-names>R.</given-names></name>
<italic>et al.</italic>
<article-title>c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription</article-title>. <source>J Exp Med</source>
<volume>194</volume>, <fpage>1021</fpage>&#x02013;<lpage>1032</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11602633</pub-id></mixed-citation></ref><ref id="b27"><mixed-citation publication-type="journal"><name><surname>Pierce</surname><given-names>J. W.</given-names></name>
<italic>et al.</italic>
<article-title>Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects <italic>in vivo</italic></article-title>. <source>J Biol Chem</source>
<volume>272</volume>, <fpage>21096</fpage>&#x02013;<lpage>21103</lpage> (<year>1997</year>).<pub-id pub-id-type="pmid">9261113</pub-id></mixed-citation></ref><ref id="b28"><mixed-citation publication-type="journal"><name><surname>Hayes</surname><given-names>M. P.</given-names></name>, <name><surname>Murphy</surname><given-names>F. J.</given-names></name> &#x00026; <name><surname>Burd</surname><given-names>P. R.</given-names></name>
<article-title>Interferon-gamma-dependent inducible expression of the human interleukin-12 p35 gene in monocytes initiates from a TATA-containing promoter distinct from the CpG-rich promoter active in Epstein-Barr virus-transformed lymphoblastoid cells</article-title>. <source>Blood</source>
<volume>91</volume>, <fpage>4645</fpage>&#x02013;<lpage>4651</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9616161</pub-id></mixed-citation></ref><ref id="b29"><mixed-citation publication-type="journal"><name><surname>Nakajima</surname><given-names>H.</given-names></name> &#x00026; <name><surname>Ihle</surname><given-names>J. N.</given-names></name>
<article-title>Granulocyte colony-stimulating factor regulates myeloid differentiation through CCAAT/enhancer-binding protein epsilon</article-title>. <source>Blood</source>
<volume>98</volume>, <fpage>897</fpage>&#x02013;<lpage>905</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11493431</pub-id></mixed-citation></ref><ref id="b30"><mixed-citation publication-type="journal"><name><surname>Friedman</surname><given-names>A. D.</given-names></name>
<italic>et al.</italic>
<article-title>Regulation of granulocyte and monocyte differentiation by CCAAT/enhancer binding protein alpha</article-title>. <source>Blood Cells Mol Dis</source>
<volume>31</volume>, <fpage>338</fpage>&#x02013;<lpage>341</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">14636649</pub-id></mixed-citation></ref><ref id="b31"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>P.</given-names></name>
<italic>et al.</italic>
<article-title>Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis</article-title>. <source>J Exp Med</source>
<volume>188</volume>, <fpage>1173</fpage>&#x02013;<lpage>1184</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9743535</pub-id></mixed-citation></ref><ref id="b32"><mixed-citation publication-type="journal"><name><surname>Radomska</surname><given-names>H. S.</given-names></name>
<italic>et al.</italic>
<article-title>CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors</article-title>. <source>Mol Cell Biol</source>
<volume>18</volume>, <fpage>4301</fpage>&#x02013;<lpage>4314</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9632814</pub-id></mixed-citation></ref><ref id="b33"><mixed-citation publication-type="journal"><name><surname>Pabst</surname><given-names>T.</given-names></name> &#x00026; <name><surname>Mueller</surname><given-names>B. U.</given-names></name>
<article-title>Transcriptional dysregulation during myeloid transformation in AML</article-title>. <source>Oncogene</source>
<volume>26</volume>, <fpage>6829</fpage>&#x02013;<lpage>6837</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17934489</pub-id></mixed-citation></ref><ref id="b34"><mixed-citation publication-type="journal"><name><surname>Marks</surname><given-names>D. J.</given-names></name>
<italic>et al.</italic>
<article-title>Defective acute inflammation in Crohn&#x02019;s disease: a clinical investigation</article-title>. <source>Lancet</source>
<volume>367</volume>, <fpage>668</fpage>&#x02013;<lpage>678</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16503465</pub-id></mixed-citation></ref><ref id="b35"><mixed-citation publication-type="journal"><name><surname>Nerlov</surname><given-names>C.</given-names></name> &#x00026; <name><surname>Ziff</surname><given-names>E. B.</given-names></name>
<article-title>CCAAT/enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability co-operate to activate transcription in both yeast and mammalian cells</article-title>. <source>Embo J</source>
<volume>14</volume>, <fpage>4318</fpage>&#x02013;<lpage>4328</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7556073</pub-id></mixed-citation></ref><ref id="b36"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y.</given-names></name> &#x00026; <name><surname>Ma</surname><given-names>X.</given-names></name>
<article-title>Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha</article-title>. <source>J Immunol</source>
<volume>184</volume>, <fpage>3866</fpage>&#x02013;<lpage>3877</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20194724</pub-id></mixed-citation></ref><ref id="b37"><mixed-citation publication-type="journal"><name><surname>Cha</surname><given-names>H. C.</given-names></name>
<italic>et al.</italic>
<article-title>Phosphorylation of CCAAT/enhancer-binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes</article-title>. <source>J Biol Chem</source>
<volume>283</volume>, <fpage>18002</fpage>&#x02013;<lpage>18011</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18408001</pub-id></mixed-citation></ref><ref id="b38"><mixed-citation publication-type="journal"><name><surname>Datta</surname><given-names>J.</given-names></name>
<italic>et al.</italic>
<article-title>Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade</article-title>. <source>Cancer Res</source>
<volume>67</volume>, <fpage>2736</fpage>&#x02013;<lpage>2746</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17363595</pub-id></mixed-citation></ref><ref id="b39"><mixed-citation publication-type="journal"><name><surname>Behre</surname><given-names>G.</given-names></name>
<italic>et al.</italic>
<article-title>Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248</article-title>. <source>J Biol Chem</source>
<volume>277</volume>, <fpage>26293</fpage>&#x02013;<lpage>26299</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11978795</pub-id></mixed-citation></ref><ref id="b40"><mixed-citation publication-type="journal"><name><surname>Salucci</surname><given-names>V.</given-names></name>
<italic>et al.</italic>
<article-title>Monocyte-derived dendritic cells from Crohn patients show differential NOD2/CARD15-dependent immune responses to bacteria</article-title>. <source>Inflamm Bowel Dis</source>
<volume>14</volume>, <fpage>812</fpage>&#x02013;<lpage>818</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18240302</pub-id></mixed-citation></ref><ref id="b41"><mixed-citation publication-type="journal"><name><surname>Bootcov</surname><given-names>M. R.</given-names></name>
<italic>et al.</italic>
<article-title>MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>94</volume>, <fpage>11514</fpage>&#x02013;<lpage>11519</lpage> (<year>1997</year>).<pub-id pub-id-type="pmid">9326641</pub-id></mixed-citation></ref><ref id="b42"><mixed-citation publication-type="journal"><name><surname>Unsicker</surname><given-names>K.</given-names></name>, <name><surname>Spittau</surname><given-names>B.</given-names></name> &#x00026; <name><surname>Krieglstein</surname><given-names>K.</given-names></name>
<article-title>The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1</article-title>. <source>Cytokine Growth Factor Rev</source>
<volume>24</volume>, <fpage>373</fpage>&#x02013;<lpage>384</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23787157</pub-id></mixed-citation></ref><ref id="b43"><mixed-citation publication-type="journal"><name><surname>Corre</surname><given-names>J.</given-names></name>, <name><surname>Hebraud</surname><given-names>B.</given-names></name> &#x00026; <name><surname>Bourin</surname><given-names>P.</given-names></name>
<article-title>Concise review: growth differentiation factor 15 in pathology: a clinical role?</article-title>
<source>Stem Cells Transl Med</source>
<volume>2</volume>, <fpage>946</fpage>&#x02013;<lpage>952</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">24191265</pub-id></mixed-citation></ref><ref id="b44"><mixed-citation publication-type="journal"><name><surname>Parkes</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn&#x02019;s disease susceptibility</article-title>. <source>Nat Genet</source>
<volume>39</volume>, <fpage>830</fpage>&#x02013;<lpage>832</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17554261</pub-id></mixed-citation></ref><ref id="b45"><mixed-citation publication-type="journal"><name><surname>Franke</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Genome-wide meta-analysis increases to 71 the number of confirmed Crohn&#x02019;s disease susceptibility loci</article-title>. <source>Nat Genet</source>
<volume>42</volume>, <fpage>1118</fpage>&#x02013;<lpage>1125</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">21102463</pub-id></mixed-citation></ref><ref id="b46"><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>J. C.</given-names></name>
<italic>et al.</italic>
<article-title>Genome-wide association defines more than 30 distinct susceptibility loci for Crohn&#x02019;s disease</article-title>. <source>Nat Genet</source>
<volume>40</volume>, <fpage>955</fpage>&#x02013;<lpage>962</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18587394</pub-id></mixed-citation></ref><ref id="b47"><mixed-citation publication-type="journal"><name><surname>Glas</surname><given-names>J.</given-names></name>
<italic>et al.</italic>
<article-title>PTPN2 gene variants are associated with susceptibility to both Crohn&#x02019;s disease and ulcerative colitis supporting a common genetic disease background</article-title>. <source>PLoS One</source>
<volume>7</volume>, <fpage>e33682</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22457781</pub-id></mixed-citation></ref><ref id="b48"><mixed-citation publication-type="journal"><name><surname>Alex</surname><given-names>P.</given-names></name>
<italic>et al.</italic>
<article-title>Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis</article-title>. <source>Inflamm Bowel Dis</source>
<volume>15</volume>, <fpage>341</fpage>&#x02013;<lpage>352</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">18942757</pub-id></mixed-citation></ref><ref id="b49"><mixed-citation publication-type="journal"><name><surname>Sarra</surname><given-names>M.</given-names></name>, <name><surname>Pallone</surname><given-names>F.</given-names></name>, <name><surname>Macdonald</surname><given-names>T. T.</given-names></name> &#x00026; <name><surname>Monteleone</surname><given-names>G.</given-names></name>
<article-title>IL-23/IL-17 axis in IBD</article-title>. <source>Inflamm Bowel Dis</source>
<volume>16</volume>, <fpage>1808</fpage>&#x02013;<lpage>1813</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20222127</pub-id></mixed-citation></ref><ref id="b50"><mixed-citation publication-type="journal"><name><surname>Holler</surname><given-names>E.</given-names></name>
<italic>et al.</italic>
<article-title>Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination</article-title>. <source>Blood</source>
<volume>107</volume>, <fpage>4189</fpage>&#x02013;<lpage>4193</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16424393</pub-id></mixed-citation></ref><ref id="b51"><mixed-citation publication-type="journal"><name><surname>Biswas</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>107</volume>, <fpage>14739</fpage>&#x02013;<lpage>14744</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20679225</pub-id></mixed-citation></ref><ref id="b52"><mixed-citation publication-type="journal"><name><surname>Morosky</surname><given-names>S. A.</given-names></name>, <name><surname>Zhu</surname><given-names>J.</given-names></name>, <name><surname>Mukherjee</surname><given-names>A.</given-names></name>, <name><surname>Sarkar</surname><given-names>S. N.</given-names></name> &#x00026; <name><surname>Coyne</surname><given-names>C. B.</given-names></name>
<article-title>Retinoic acid-induced gene-I (RIG-I) associates with nucleotide-binding oligomerization domain-2 (NOD2) to negatively regulate inflammatory signaling</article-title>. <source>J Biol Chem</source>
<volume>286</volume>, <fpage>28574</fpage>&#x02013;<lpage>28583</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21690088</pub-id></mixed-citation></ref><ref id="b53"><mixed-citation publication-type="journal"><name><surname>Kapoor</surname><given-names>A.</given-names></name>, <name><surname>Forman</surname><given-names>M.</given-names></name> &#x00026; <name><surname>Arav-Boger</surname><given-names>R.</given-names></name>
<article-title>Activation of nucleotide oligomerization domain 2 (NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus replication</article-title>. <source>PLoS One</source>
<volume>9</volume>, <fpage>e92704</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24671169</pub-id></mixed-citation></ref><ref id="b54"><mixed-citation publication-type="journal"><name><surname>Folwaczny</surname><given-names>C.</given-names></name>, <name><surname>Glas</surname><given-names>J.</given-names></name> &#x00026; <name><surname>Torok</surname><given-names>H. P.</given-names></name>
<article-title>Crohn&#x02019;s disease: an immunodeficiency?</article-title>
<source>Eur J Gastroenterol Hepatol</source>
<volume>15</volume>, <fpage>621</fpage>&#x02013;<lpage>626</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12840672</pub-id></mixed-citation></ref><ref id="b55"><mixed-citation publication-type="journal"><name><surname>Chamberlin</surname><given-names>W. M.</given-names></name> &#x00026; <name><surname>Naser</surname><given-names>S. A.</given-names></name>
<article-title>Integrating theories of the etiology of Crohn&#x02019;s disease. On the etiology of Crohn&#x02019;s disease: questioning the hypotheses</article-title>. <source>Med Sci Monit</source>
<volume>12</volume>, <fpage>RA27</fpage>&#x02013;<lpage>33</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16449960</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p><bold>Author Contributions</bold> H.K. prepared figures 2&#x02013;6; Q.Z. prepared <xref ref-type="fig" rid="f7">figure 7</xref>; H.Z. prepared <xref ref-type="fig" rid="f8">figure 8</xref>; X.L. and T.Z. prepared <xref ref-type="fig" rid="f1">figure 1</xref>; X.M. wrote the manuscript. All authors reviewed the manuscript.</p></fn></fn-group></back><floats-group><fig id="f1"><label>Figure 1</label><caption><title>MDP-independent and dependent activities of NOD2.</title><p>Bone marrow macrophages were derived with rM-CSF from WT and NOD2-KO mice, stimulated with LPS (500&#x02009;ng/ml) with or without MDP (5&#x02009;&#x003bc;g/ml), followed by determination of expressed mRNA and secreted cytokine levels by real time PCR (<bold>a</bold>) and ELISA (<bold>b</bold>), respectively. Data represent means of three trials with SE. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-f1"/></fig><fig id="f2"><label>Figure 2</label><caption><title>Clustering analysis of RNAseq profiling in WT vs NOD2 KO macrophages.</title><p>RNA samples from WT and NOD2 KO macrophages treated with MDP or LPS or both were subjected to NexGen RNA-sequencing (whole exon). Genes of low expressions (RPKM &#x0003c;0.0) were filtered out. The RPKM values were further normalized per gene over all samples, to be specific, for each gene the mean and standard deviation (stddev) of RPKM over all samples were calculated, and the RPKM was linearly transformed using the formula (rpkm-mean)/stddev. The heatmap was then generated by heatmap.2 in the R gplots package. By default, heatmap.2 uses Euclidean measure to obtain distance matrix and complete agglomeration method for clustering.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-f2"/></fig><fig id="f3"><label>Figure 3</label><caption><title>Reciprocal regulation of LPS- and NOD2-mediated signaling in IL-12 transcription.</title><p>An IL-12p35 promoter-reporter construct was transfected into RAW264.7 cells. Twenty-four hours later, cells were stimulated for 6&#x02009;h with LPS (500&#x02009;ng/ml) in the presence of varying amounts of MDP as indicated (<bold>a</bold>), or with MDP (5&#x02009;&#x003bc;g/ml) in the presence of increasing LPS concentrations (<bold>b</bold>). Cells were then harvested and cell lysate prepared. Luciferase activity was measured. Data represents mean plus SD of three separate experiments. (<bold>c</bold>) Peripheral blood-derived primary human monocytes obtained from normal donors were stimulated with LPS (500&#x02009;ng/ml) for 6&#x02009;h in the presence or absence of MDP (5&#x02009;&#x003bc;g/ml). Total RNA was isolated and analyzed by real time quantitative PCR, and normalized against GAPDH. Data are expressed as relative levels to that of the unstimulated cells, which was set as 1. Data represent mean plus SEM of three donors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-f3"/></fig><fig id="f4"><label>Figure 4</label><caption><title>RIP2 and c-Rel in NOD2-mediated regulation of IL-12p35 and p40 expression.</title><p>Thioglycolate-elicited peritoneal macrophages from wild-type (WT), Rip2<sup>&#x02212;/&#x02212;</sup> and Crel<sup>&#x02212;/&#x02212;</sup> mice were stimulated for 6&#x02009;h with LPS (500&#x02009;ng/ml) with or without MDP (5&#x02009;&#x003bc;g/ml). RNA analyses were carried out by real time RT-PCR for (<bold>a</bold>) IL-12p35 (upper), p40 (middle), and TNF-&#x003b1; (lower). (<bold>b</bold>) Cytokines were measured from culture supernatant by ELISA for IL-12 (upper) and IL-23 (lower). (<bold>c</bold>) THP-1 cells were stimulated with LPS for 6&#x02009;h with a low dose of Bay11&#x02013;7082 (0.5&#x02009;&#x003bc;M). Levels of p35 mRNA were analyzed by real-time RT-PCR. Numbers within the bars (22% and 21%, respectively) in MDP-treated cells indicate the percentages of remaining mRNA levels in the presence of Bay11&#x02013;7082 compared to controls.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-f4"/></fig><fig id="f5"><label>Figure 5</label><caption><title>MDP regulates IL-12p35 transcription through a proximal promoter element.</title><p>Various human IL-12p35 promoter-reporter base-substitution (transversions) constructs were transfected into RAW264.7 cells. Twenty-four hours later, cells were stimulated with LPS (500&#x02009;ng/ml) in the presence of MDP (5&#x02009;&#x003bc;g/ml) for 6&#x02009;h. Cells were harvested and cell lysates prepared. Luciferase activity was measured. Data represents mean plus SD of three separate experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-f5"/></fig><fig id="f6"><label>Figure 6</label><caption><title>Role of C/EBP&#x003b1; and PKC in NOD2-mediated regulation of IL-12 expression.</title><p>(<bold>a</bold>) Macrophages from WT and conditional C/EBP&#x003b1;-deficient mice were stimulated with LPS in the presence or absence of MDP, followed by cytokine measurements by ELISA for IL-12, p40, and TNF-&#x003b1;. (<bold>b</bold>) Transient cotransfections were carried out with the human IL-12p35 reporter and one of five C/EBP&#x003b1; expression vectors: WT, S21A, S193A, T222A/T226A, S248A phosphorylation mutants. Results represent three experiments. (<bold>c</bold>) Transient cotransfections were carried out as in (b). Various amounts of the general PKC inhibitor staurosporine (Str) were added to the culture as indicated.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-f6"/></fig><fig id="f7"><label>Figure 7</label><caption><title>Role of C/EBP&#x003b1; and IL-12 in TNBS-induced colitis.</title><p>(<bold>a</bold>) TNBS colitis was induced in WT and <italic>cebp</italic>&#x003b1; KO mice. MDP was administered i.p. on days &#x02013;3, &#x02013;2, and &#x02013;1 (n&#x02009;=&#x02009;9/group). Anti-IL12 antibody (<bold>b</bold>, <bold>c</bold>) or anti-IL-23 (<bold>c</bold>), or the control IgG were administrated on days 0, and 2 (n&#x02009;=&#x02009;4/group). Mean body weight of three independent experiments with SE is represented. <bold>(c)</bold> H&#x00026;E-staining of colonic tissues of NBS-, MDP- or anti-IL-12-treated mice harvested on day 4 are shown in 100x magnification showing massive infiltration of mononuclear cells as well as destruction of crypt architecture. (<bold>d</bold>) Histology scores of the colonic tissues harvested on day 4. **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01. (<bold>f</bold>) Sera from the mice were collected on day 4 and analyzed for cytokine production by ELISA (IL-12 and IL-23p40). **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-f7"/></fig><fig id="f8"><label>Figure 8</label><caption><title>CD-associated NOD2 mutants selectively inhibit IL-12p35 transcription.</title><p>(<bold>a</bold>) Western blot analysis of human NOD2 and its variants. The expression vectors contain a FLAG tag. Following transient transfection in duplicates, whole cell lysates were analyzed with a FLAG-specific mAb. Although cropping was used in the final image presentation for the purpose of saving space (the red-box defines the cropped boundary), all lanes were taken from the same gel in the original ordering (see <xref ref-type="supplementary-material" rid="S1">Supplemental Fig. 1s</xref> for the original gel). (<bold>b</bold>) Human macrophage cell line THP-1 was transiently transfected with expression vectors for human NOD2 or its CD-associated variants as indicated. Cells were then stimulated with LPS (500&#x02009;ng/ml) in the presence or absence of MDP (5&#x02009;&#x003bc;g/ml) for 6&#x02009;h, harvested and mRNA expression of IL-12p35, p40 and IL-10 analyzed by real time RT-PCR. pcDNA3 was used as an empty control vector. Data represent four independent experiments. (<bold>c</bold>) Luciferase activity in lysates of cells transfected with the human IL12p35 promoter-luciferase reporter, together with various molar ratios of vectors encoding NOD2 and 1007fs, then stimulated for 7&#x02009;h with LPS before harvesting. Data are summary of 3 independent experiments. (<bold>d</bold>) IFN-&#x003b3; production by human PBMCs from five healthy controls and three CD patients homozygous for 1007fs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep12018-f8"/></fig><table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Differentially expressed genes in LPS-activated WT and NOD2 KO macrophages.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">Gene_id</th><th align="center" valign="top" charoff="50">Refseq_id</th><th align="center" valign="top" char="." charoff="50">WT (+LPS)</th><th align="center" valign="top" char="." charoff="50">NOD2 KO (+LPS)</th><th align="center" valign="top" char="." charoff="50">Fold_change</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Gdf15 (growth differentiation factor 15)</td><td align="center" valign="top" charoff="50">NM_011819</td><td align="center" valign="top" char="." charoff="50">65.24</td><td align="center" valign="top" char="." charoff="50">2.84</td><td align="center" valign="top" char="." charoff="50">+23.0</td></tr><tr><td align="left" valign="top" charoff="50">BC100530 (unannotated)</td><td align="center" valign="top" charoff="50">NM_001082546</td><td align="center" valign="top" char="." charoff="50">2.89</td><td align="center" valign="top" char="." charoff="50">367.83</td><td align="center" valign="top" char="." charoff="50">&#x02212;127.1</td></tr><tr><td align="left" valign="top" charoff="50">Stfa1 (stefin A1)</td><td align="center" valign="top" charoff="50">NM_001082543</td><td align="center" valign="top" char="." charoff="50">2.49</td><td align="center" valign="top" char="." charoff="50">310.22</td><td align="center" valign="top" char="." charoff="50">&#x02212;124.7</td></tr><tr><td align="left" valign="top" charoff="50">Mpo (myeloperoxidase)</td><td align="center" valign="top" charoff="50">NM_010824</td><td align="center" valign="top" char="." charoff="50">2.06</td><td align="center" valign="top" char="." charoff="50">195.71</td><td align="center" valign="top" char="." charoff="50">&#x02212;95.2</td></tr><tr><td align="left" valign="top" charoff="50">Ctsg (cathepsin G)</td><td align="center" valign="top" charoff="50">NM_007800</td><td align="center" valign="top" char="." charoff="50">2.48</td><td align="center" valign="top" char="." charoff="50">220.09</td><td align="center" valign="top" char="." charoff="50">&#x02212;88.7</td></tr><tr><td align="left" valign="top" charoff="50">Stfa2 (stefin A2)</td><td align="center" valign="top" charoff="50">NM_001082545</td><td align="center" valign="top" char="." charoff="50">1.63</td><td align="center" valign="top" char="." charoff="50">135.43</td><td align="center" valign="top" char="." charoff="50">&#x02212;83.2</td></tr><tr><td align="left" valign="top" charoff="50">Ngp (neutrophilic granule protein)</td><td align="center" valign="top" charoff="50">NM_008694</td><td align="center" valign="top" char="." charoff="50">8.17</td><td align="center" valign="top" char="." charoff="50">578.86</td><td align="center" valign="top" char="." charoff="50">&#x02212;70.8</td></tr><tr><td align="left" valign="top" charoff="50">Ms4a3 (membrane-spanning 4-domains, subfamily A, member 3)</td><td align="center" valign="top" charoff="50">NM_133246</td><td align="center" valign="top" char="." charoff="50">2.20</td><td align="center" valign="top" char="." charoff="50">151.74</td><td align="center" valign="top" char="." charoff="50">&#x02212;69.1</td></tr><tr><td align="left" valign="top" charoff="50">Prtn3 (proteinase 3)</td><td align="center" valign="top" charoff="50">NM_011178</td><td align="center" valign="top" char="." charoff="50">2.94</td><td align="center" valign="top" char="." charoff="50">192.43</td><td align="center" valign="top" char="." charoff="50">&#x02212;65.4</td></tr><tr><td align="left" valign="top" charoff="50">Stfa2l1 (stefin A2 like 1)</td><td align="center" valign="top" charoff="50">NM_173869</td><td align="center" valign="top" char="." charoff="50">2.33</td><td align="center" valign="top" char="." charoff="50">139.49</td><td align="center" valign="top" char="." charoff="50">&#x02212;59.9</td></tr><tr><td align="left" valign="top" charoff="50">S100a9 (S100 calcium binding protein A9)</td><td align="center" valign="top" charoff="50">NM_009114</td><td align="center" valign="top" char="." charoff="50">69.85</td><td align="center" valign="top" char="." charoff="50">3561.00</td><td align="center" valign="top" char="." charoff="50">&#x02212;51.0</td></tr><tr><td align="left" valign="top" charoff="50">Pglyrp1 (peptidoglycan recognition protein 1)</td><td align="center" valign="top" charoff="50">NM_009402</td><td align="center" valign="top" char="." charoff="50">1.43</td><td align="center" valign="top" char="." charoff="50">66.34</td><td align="center" valign="top" char="." charoff="50">&#x02212;46.4</td></tr><tr><td align="left" valign="top" charoff="50">Ltf (lactotransferrin)</td><td align="center" valign="top" charoff="50">NM_008522</td><td align="center" valign="top" char="." charoff="50">1.24</td><td align="center" valign="top" char="." charoff="50">55.51</td><td align="center" valign="top" char="." charoff="50">&#x02212;44.6</td></tr><tr><td align="left" valign="top" charoff="50">Gm5483 (predicted gene 5483)</td><td align="center" valign="top" charoff="50">NM_001082547</td><td align="center" valign="top" char="." charoff="50">8.52</td><td align="center" valign="top" char="." charoff="50">367.49</td><td align="center" valign="top" char="." charoff="50">&#x02212;43.1</td></tr><tr><td align="left" valign="top" charoff="50">Camp (cathelicidin antimicrobial peptide)</td><td align="center" valign="top" charoff="50">NM_009921</td><td align="center" valign="top" char="." charoff="50">4.49</td><td align="center" valign="top" char="." charoff="50">130.54</td><td align="center" valign="top" char="." charoff="50">&#x02212;29.1</td></tr><tr><td align="left" valign="top" charoff="50">Ccnb1 (cyclin B1)</td><td align="center" valign="top" charoff="50">NM_172301</td><td align="center" valign="top" char="." charoff="50">1.34</td><td align="center" valign="top" char="." charoff="50">31.71</td><td align="center" valign="top" char="." charoff="50">&#x02212;23.7</td></tr><tr><td align="left" valign="top" charoff="50">Rrm2 (ribonucleotide reductase M2)</td><td align="center" valign="top" charoff="50">NM_009104</td><td align="center" valign="top" char="." charoff="50">3.02</td><td align="center" valign="top" char="." charoff="50">61.69</td><td align="center" valign="top" char="." charoff="50">&#x02212;20.4</td></tr><tr><td align="left" valign="top" charoff="50">Chi3l3 (chitinase-like 3)</td><td align="center" valign="top" charoff="50">NM_009892</td><td align="center" valign="top" char="." charoff="50">18.92</td><td align="center" valign="top" char="." charoff="50">372.37</td><td align="center" valign="top" char="." charoff="50">&#x02212;19.7</td></tr><tr><td align="left" valign="top" charoff="50">Gm5416 (predicted gene 5416)</td><td align="center" valign="top" charoff="50">NM_001082542</td><td align="center" valign="top" char="." charoff="50">3.39</td><td align="center" valign="top" char="." charoff="50">65.36</td><td align="center" valign="top" char="." charoff="50">&#x02212;19.3</td></tr><tr><td align="left" valign="top" charoff="50">Ifitm1 (interferon induced transmembrane protein 1)</td><td align="center" valign="top" charoff="50">NM_001112715, NM_026820</td><td align="center" valign="top" char="." charoff="50">13.31</td><td align="center" valign="top" char="." charoff="50">251.88</td><td align="center" valign="top" char="." charoff="50">&#x02212;18.9</td></tr><tr><td align="left" valign="top" charoff="50">Cenpa (centromere protein A)</td><td align="center" valign="top" charoff="50">NM_007681</td><td align="center" valign="top" char="." charoff="50">1.11</td><td align="center" valign="top" char="." charoff="50">20.85</td><td align="center" valign="top" char="." charoff="50">&#x02212;18.8</td></tr><tr><td align="left" valign="top" charoff="50">Ly6c2 (lymphocyte antigen 6 complex, locus C2)</td><td align="center" valign="top" charoff="50">NM_001099217</td><td align="center" valign="top" char="." charoff="50">43.30</td><td align="center" valign="top" char="." charoff="50">790.80</td><td align="center" valign="top" char="." charoff="50">&#x02212;18.3</td></tr><tr><td align="left" valign="top" charoff="50">Birc5 (baculoviral IAP repeat-containing 5)</td><td align="center" valign="top" charoff="50">NM_009689, NM_001012273</td><td align="center" valign="top" char="." charoff="50">2.24</td><td align="center" valign="top" char="." charoff="50">39.67</td><td align="center" valign="top" char="." charoff="50">&#x02212;17.7</td></tr><tr><td align="left" valign="top" charoff="50">Lmnb1 (lamin B1)</td><td align="center" valign="top" charoff="50">NM_010721</td><td align="center" valign="top" char="." charoff="50">1.81</td><td align="center" valign="top" char="." charoff="50">31.49</td><td align="center" valign="top" char="." charoff="50">&#x02212;17.4</td></tr><tr><td align="left" valign="top" charoff="50">Ube2c (ubiquitin-conjugating enzyme E2C)</td><td align="center" valign="top" charoff="50">NM_026785</td><td align="center" valign="top" char="." charoff="50">3.01</td><td align="center" valign="top" char="." charoff="50">51.79</td><td align="center" valign="top" char="." charoff="50">&#x02212;17.2</td></tr><tr><td align="left" valign="top" charoff="50">2810417H13Rik (RIKEN cDNA 2810417H13 gene)</td><td align="center" valign="top" charoff="50">NM_026515</td><td align="center" valign="top" char="." charoff="50">3.39</td><td align="center" valign="top" char="." charoff="50">56.80</td><td align="center" valign="top" char="." charoff="50">&#x02212;16.8</td></tr><tr><td align="left" valign="top" charoff="50">Cdca3 (cell division cycle associated 3)</td><td align="center" valign="top" charoff="50">NM_013538</td><td align="center" valign="top" char="." charoff="50">1.28</td><td align="center" valign="top" char="." charoff="50">21.25</td><td align="center" valign="top" char="." charoff="50">&#x02212;16.7</td></tr><tr><td align="left" valign="top" charoff="50">Phgdh (3-phosphoglycerate dehydrogenase)</td><td align="center" valign="top" charoff="50">NM_016966</td><td align="center" valign="top" char="." charoff="50">2.59</td><td align="center" valign="top" char="." charoff="50">41.79</td><td align="center" valign="top" char="." charoff="50">&#x02212;16.2</td></tr><tr><td align="left" valign="top" charoff="50">Prc1 (protein regulator of cytokinesis 1)</td><td align="center" valign="top" charoff="50">NM_145150</td><td align="center" valign="top" char="." charoff="50">1.12</td><td align="center" valign="top" char="." charoff="50">17.55</td><td align="center" valign="top" char="." charoff="50">&#x02212;15.7</td></tr><tr><td align="left" valign="top" charoff="50">Chil1 (chitinase-like 1)</td><td align="center" valign="top" charoff="50">NM_007695</td><td align="center" valign="top" char="." charoff="50">2.78</td><td align="center" valign="top" char="." charoff="50">42.21</td><td align="center" valign="top" char="." charoff="50">&#x02212;15.2</td></tr><tr><td align="left" valign="top" charoff="50">Nusap1(nucleolar and spindle associated protein 1)</td><td align="center" valign="top" charoff="50">NM_133851, NM_001042652</td><td align="center" valign="top" char="." charoff="50">1.12</td><td align="center" valign="top" char="." charoff="50">16.97</td><td align="center" valign="top" char="." charoff="50">&#x02212;15.2</td></tr><tr><td align="left" valign="top" charoff="50">Cdca8(cell division cycle associated 8)</td><td align="center" valign="top" charoff="50">NM_026560</td><td align="center" valign="top" char="." charoff="50">1.92</td><td align="center" valign="top" char="." charoff="50">25.78</td><td align="center" valign="top" char="." charoff="50">&#x02212;13.4</td></tr><tr><td align="left" valign="top" charoff="50">Top2a(topoisomerase (DNA) II alpha)</td><td align="center" valign="top" charoff="50">NM_011623</td><td align="center" valign="top" char="." charoff="50">3.18</td><td align="center" valign="top" char="." charoff="50">42.06</td><td align="center" valign="top" char="." charoff="50">&#x02212;13.2</td></tr><tr><td align="left" valign="top" charoff="50">Ccna2(cyclin A2)</td><td align="center" valign="top" charoff="50">NM_009828</td><td align="center" valign="top" char="." charoff="50">2.10</td><td align="center" valign="top" char="." charoff="50">27.53</td><td align="center" valign="top" char="." charoff="50">&#x02212;13.1</td></tr><tr><td align="left" valign="top" charoff="50">Serpinb1a(serine (or cysteine) peptidase inhibitor, clade B, member 1a)</td><td align="center" valign="top" charoff="50">NM_025429</td><td align="center" valign="top" char="." charoff="50">2.19</td><td align="center" valign="top" char="." charoff="50">21.06</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.6</td></tr><tr><td align="left" valign="top" charoff="50">Uhrf1 (ubiquitin-like, containing PHD and RING finger domains, 1)</td><td align="center" valign="top" charoff="50">NM_001111078, NM_001111080, NM_001111079, NM_010931</td><td align="center" valign="top" char="." charoff="50">1.42</td><td align="center" valign="top" char="." charoff="50">13.36</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.4</td></tr><tr><td align="left" valign="top" charoff="50">Tk1 (thymidine kinase 1)</td><td align="center" valign="top" charoff="50">NM_009387, NM_001271729</td><td align="center" valign="top" char="." charoff="50">1.31</td><td align="center" valign="top" char="." charoff="50">12.29</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.4</td></tr><tr><td align="left" valign="top" charoff="50">Hells (helicase, lymphoid specific)</td><td align="center" valign="top" charoff="50">NM_008234</td><td align="center" valign="top" char="." charoff="50">1.42</td><td align="center" valign="top" char="." charoff="50">13.37</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.4</td></tr><tr><td align="left" valign="top" charoff="50">Stfa3 (stefin A3)</td><td align="center" valign="top" charoff="50">NM_025288</td><td align="center" valign="top" char="." charoff="50">92.96</td><td align="center" valign="top" char="." charoff="50">860.86</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.3</td></tr><tr><td align="left" valign="top" charoff="50">Tacc3 (transforming, acidic coiled-coil containing protein 3)</td><td align="center" valign="top" charoff="50">NM_001040435</td><td align="center" valign="top" char="." charoff="50">2.61</td><td align="center" valign="top" char="." charoff="50">24.05</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.2</td></tr><tr><td align="left" valign="top" charoff="50">Rad51 (RAD51 homolog)</td><td align="center" valign="top" charoff="50">NM_011234</td><td align="center" valign="top" char="." charoff="50">1.50</td><td align="center" valign="top" char="." charoff="50">13.76</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.2</td></tr><tr><td align="left" valign="top" charoff="50">Rab27a (RAB27A, member RAS oncogene family)</td><td align="center" valign="top" charoff="50">NM_023635</td><td align="center" valign="top" char="." charoff="50">1.12</td><td align="center" valign="top" char="." charoff="50">10.13</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.0</td></tr><tr><td align="left" valign="top" charoff="50">Prim1(DNA primase, p49 subunit)</td><td align="center" valign="top" charoff="50">NM_008921</td><td align="center" valign="top" char="." charoff="50">1.27</td><td align="center" valign="top" char="." charoff="50">11.48</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.0</td></tr><tr><td align="left" valign="top" charoff="50">Mcm10(minichromosome maintenance deficient 10)</td><td align="center" valign="top" charoff="50">NM_027290</td><td align="center" valign="top" char="." charoff="50">1.56</td><td align="center" valign="top" char="." charoff="50">14.01</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.0</td></tr><tr><td align="left" valign="top" charoff="50">Rrm1(ribonucleotide reductase M1)</td><td align="center" valign="top" charoff="50">NM_009103</td><td align="center" valign="top" char="." charoff="50">3.99</td><td align="center" valign="top" char="." charoff="50">35.64</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.9</td></tr><tr><td align="left" valign="top" charoff="50">Zwilch(zwilch kinetochore protein)</td><td align="center" valign="top" charoff="50">NM_026507</td><td align="center" valign="top" char="." charoff="50">1.00</td><td align="center" valign="top" char="." charoff="50">8.77</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.7</td></tr><tr><td align="left" valign="top" charoff="50">2010005H15Rik(RIKEN cDNA 2010005H15 gene)</td><td align="center" valign="top" charoff="50">NM_029733</td><td align="center" valign="top" char="." charoff="50">13.79</td><td align="center" valign="top" char="." charoff="50">120.04</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.7</td></tr><tr><td align="left" valign="top" charoff="50">Smc2(structural maintenance of chromosomes 2)</td><td align="center" valign="top" charoff="50">NM_008017</td><td align="center" valign="top" char="." charoff="50">2.23</td><td align="center" valign="top" char="." charoff="50">19.11</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.6</td></tr><tr><td align="left" valign="top" charoff="50">Cks2(CDC28 protein kinase regulatory subunit 2)</td><td align="center" valign="top" charoff="50">NM_025415</td><td align="center" valign="top" char="." charoff="50">6.73</td><td align="center" valign="top" char="." charoff="50">55.78</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.3</td></tr><tr><td align="left" valign="top" charoff="50">Sell(selectin, lymphocyte)</td><td align="center" valign="top" charoff="50">NM_001164059, NM_011346</td><td align="center" valign="top" char="." charoff="50">9.07</td><td align="center" valign="top" char="." charoff="50">74.18</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.2</td></tr><tr><td align="left" valign="top" charoff="50">Gm15056(predicted gene 15056)</td><td align="center" valign="top" charoff="50">NM_001177471</td><td align="center" valign="top" char="." charoff="50">1.47</td><td align="center" valign="top" char="." charoff="50">11.98</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.2</td></tr><tr><td align="left" valign="top" charoff="50">Uck2(uridine-cytidine kinase 2)</td><td align="center" valign="top" charoff="50">NM_030724</td><td align="center" valign="top" char="." charoff="50">2.31</td><td align="center" valign="top" char="." charoff="50">18.62</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.1</td></tr><tr><td align="left" valign="top" charoff="50">Lbr(lamin B receptor)</td><td align="center" valign="top" charoff="50">NM_133815</td><td align="center" valign="top" char="." charoff="50">1.77</td><td align="center" valign="top" char="." charoff="50">13.97</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.9</td></tr><tr><td align="left" valign="top" charoff="50">Rfc4(replication factor C (activator 1) 4)</td><td align="center" valign="top" charoff="50">NM_145480</td><td align="center" valign="top" char="." charoff="50">1.34</td><td align="center" valign="top" char="." charoff="50">10.34</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.7</td></tr><tr><td align="left" valign="top" charoff="50">Tipin(timeless interacting protein)</td><td align="center" valign="top" charoff="50">NM_025372</td><td align="center" valign="top" char="." charoff="50">2.76</td><td align="center" valign="top" char="." charoff="50">20.83</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.6</td></tr><tr><td align="left" valign="top" charoff="50">Cdk1(cyclin-dependent kinase 1)</td><td align="center" valign="top" charoff="50">NM_007659</td><td align="center" valign="top" char="." charoff="50">3.02</td><td align="center" valign="top" char="." charoff="50">22.83</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.6</td></tr><tr><td align="left" valign="top" charoff="50">Oip5(Opa interacting protein 5)</td><td align="center" valign="top" charoff="50">NM_001042653</td><td align="center" valign="top" char="." charoff="50">1.30</td><td align="center" valign="top" char="." charoff="50">9.79</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.5</td></tr><tr><td align="left" valign="top" charoff="50">Cks1b(CDC28 protein kinase 1b)</td><td align="center" valign="top" charoff="50">NM_016904</td><td align="center" valign="top" char="." charoff="50">5.54</td><td align="center" valign="top" char="." charoff="50">41.58</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.5</td></tr><tr><td align="left" valign="top" charoff="50">1100001G20Rik(WAP four-disulfide core domain 21)</td><td align="center" valign="top" charoff="50">NM_183249</td><td align="center" valign="top" char="." charoff="50">55.58</td><td align="center" valign="top" char="." charoff="50">401.58</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.2</td></tr><tr><td align="left" valign="top" charoff="50">Hmgn2(high mobility group nucleosomal binding domain 2)</td><td align="center" valign="top" charoff="50">NM_016957</td><td align="center" valign="top" char="." charoff="50">38.26</td><td align="center" valign="top" char="." charoff="50">275.98</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.2</td></tr><tr><td align="left" valign="top" charoff="50">Mcm5(minichromosome maintenance deficient 5, cell division cycle 46)</td><td align="center" valign="top" charoff="50">NM_008566</td><td align="center" valign="top" char="." charoff="50">3.49</td><td align="center" valign="top" char="." charoff="50">24.77</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.1</td></tr><tr><td align="left" valign="top" charoff="50">Mcm2(minichromosome maintenance deficient 2 mitotin)</td><td align="center" valign="top" charoff="50">NM_008564</td><td align="center" valign="top" char="." charoff="50">2.68</td><td align="center" valign="top" char="." charoff="50">18.69</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.0</td></tr><tr><td align="left" valign="top" charoff="50">Ltb4r1(leukotriene B4 receptor 1)</td><td align="center" valign="top" charoff="50">NM_008519</td><td align="center" valign="top" char="." charoff="50">1.26</td><td align="center" valign="top" char="." charoff="50">8.76</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.9</td></tr><tr><td align="left" valign="top" charoff="50">Lipg(lipase, endothelial)</td><td align="center" valign="top" charoff="50">NM_010720</td><td align="center" valign="top" char="." charoff="50">3.34</td><td align="center" valign="top" char="." charoff="50">23.00</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.9</td></tr><tr><td align="left" valign="top" charoff="50">Fignl1(fidgetin-like 1)</td><td align="center" valign="top" charoff="50">NM_021891, NM_001163360, NM_001163359</td><td align="center" valign="top" char="." charoff="50">1.80</td><td align="center" valign="top" char="." charoff="50">12.10</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.7</td></tr><tr><td align="left" valign="top" charoff="50">Cenpe(centromere protein E)</td><td align="center" valign="top" charoff="50">NM_173762</td><td align="center" valign="top" char="." charoff="50">1.36</td><td align="center" valign="top" char="." charoff="50">8.86</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.5</td></tr><tr><td align="left" valign="top" charoff="50">Asf1b(anti-silencing function 1B histone chaperone)</td><td align="center" valign="top" charoff="50">NM_024184</td><td align="center" valign="top" char="." charoff="50">2.27</td><td align="center" valign="top" char="." charoff="50">14.70</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.5</td></tr><tr><td align="left" valign="top" charoff="50">Mcm3(minichromosome maintenance deficient 3)</td><td align="center" valign="top" charoff="50">NM_008563</td><td align="center" valign="top" char="." charoff="50">5.19</td><td align="center" valign="top" char="." charoff="50">33.55</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.5</td></tr><tr><td align="left" valign="top" charoff="50">Gins1(GINS complex subunit 1 (Psf1 homolog))</td><td align="center" valign="top" charoff="50">NM_001163476, NM_027014</td><td align="center" valign="top" char="." charoff="50">1.65</td><td align="center" valign="top" char="." charoff="50">10.61</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.4</td></tr><tr><td align="left" valign="top" charoff="50">Mcm4(minichromosome maintenance deficient 4 homolog)</td><td align="center" valign="top" charoff="50">NM_008565</td><td align="center" valign="top" char="." charoff="50">3.03</td><td align="center" valign="top" char="." charoff="50">19.02</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.3</td></tr><tr><td align="left" valign="top" charoff="50">Arhgap19(Rho GTPase activating protein 19)</td><td align="center" valign="top" charoff="50">NM_001163495, NM_027667</td><td align="center" valign="top" char="." charoff="50">1.18</td><td align="center" valign="top" char="." charoff="50">7.22</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.1</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Differentially expressed genes in WT and NOD2 KO macrophages treated with LPS. Bone marrow macrophages from WT and NOD2 KO mice were stimulated with LPS with or without MDP. Total RNA were extracted for RNA-seq analysis. Criteria for selection of genes: minimum expression level: 1; minimum fold change: 6.0, which is the threshold level that can be reliably corroborated by real time RT-PCR. Positive values represent expression ratios of WT/KO whereas negative values represent KO/WT ratios. Criteria for selection of genes: minimum expression level: 1; minimum fold change: 6.0, which is the threshold level that can be reliably corroborated by real time RT-PCR. Positive values represent expression ratios of WT/KO whereas negative values represent KO/WT ratios.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><title>Genes differentially expressed in WT vs NOD2 KO macrophages treated with MDP and LPS.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" char="." charoff="50">Expression Level<hr/></th><th align="center" valign="top" char="." charoff="50">&#x000a0;</th></tr><tr><th align="left" valign="top" charoff="50">Gene_id/Gene_name</th><th align="center" valign="top" charoff="50">Refseq_id</th><th align="center" valign="top" char="." charoff="50">WT (LPS+MDP)</th><th align="center" valign="top" char="." charoff="50">NOD2 KO (LPS+MDP)</th><th align="center" valign="top" char="." charoff="50">Fold_change</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Gdf15 (growth differentiation factor 15)</td><td align="center" valign="top" charoff="50">NM_011819</td><td align="center" valign="top" char="." charoff="50">60.00</td><td align="center" valign="top" char="." charoff="50">3.74</td><td align="center" valign="top" char="." charoff="50">+16.0</td></tr><tr><td align="left" valign="top" charoff="50">H2-M2 (histocompatibility 2, M region locus 2)</td><td align="center" valign="top" charoff="50">NM_008204</td><td align="center" valign="top" char="." charoff="50">36.32</td><td align="center" valign="top" char="." charoff="50">2.96</td><td align="center" valign="top" char="." charoff="50">+12.3</td></tr><tr><td align="left" valign="top" charoff="50">Sdc1 (syndecan 1)</td><td align="center" valign="top" charoff="50">NM_011519</td><td align="center" valign="top" char="." charoff="50">29.50</td><td align="center" valign="top" char="." charoff="50">4.15</td><td align="center" valign="top" char="." charoff="50">+7.1</td></tr><tr><td align="left" valign="top" charoff="50">H2-L (histocompatibility 2, D region locus L)</td><td align="center" valign="top" charoff="50">NM_001267808</td><td align="center" valign="top" char="." charoff="50">198.33</td><td align="center" valign="top" char="." charoff="50">29.70</td><td align="center" valign="top" char="." charoff="50">+6.7</td></tr><tr><td align="left" valign="top" charoff="50">Igfbp7 (insulin-like growth factor binding protein 7)</td><td align="center" valign="top" charoff="50">NM_001159518, NM_008048</td><td align="center" valign="top" char="." charoff="50">7.22</td><td align="center" valign="top" char="." charoff="50">1.21</td><td align="center" valign="top" char="." charoff="50">+6.0</td></tr><tr><td align="left" valign="top" charoff="50">Ngp (neutrophilic granule protein)</td><td align="center" valign="top" charoff="50">NM_008694</td><td align="center" valign="top" char="." charoff="50">1.68</td><td align="center" valign="top" char="." charoff="50">672.15</td><td align="center" valign="top" char="." charoff="50">&#x02212;399.4</td></tr><tr><td align="left" valign="top" charoff="50">Stfa1 (stefin A1)</td><td align="center" valign="top" charoff="50">NM_001082543</td><td align="center" valign="top" char="." charoff="50">1.77</td><td align="center" valign="top" char="." charoff="50">400.15</td><td align="center" valign="top" char="." charoff="50">&#x02212;226.2</td></tr><tr><td align="left" valign="top" charoff="50">BC100530 (stefin A-like protein)</td><td align="center" valign="top" charoff="50">NM_001082546</td><td align="center" valign="top" char="." charoff="50">2.66</td><td align="center" valign="top" char="." charoff="50">498.98</td><td align="center" valign="top" char="." charoff="50">&#x02212;187.6</td></tr><tr><td align="left" valign="top" charoff="50">Prtn3 (proteinase 3)</td><td align="center" valign="top" charoff="50">NM_011178</td><td align="center" valign="top" char="." charoff="50">1.20</td><td align="center" valign="top" char="." charoff="50">210.26</td><td align="center" valign="top" char="." charoff="50">&#x02212;175.3</td></tr><tr><td align="left" valign="top" charoff="50">Stfa2l1 (stefin A2 like 1)</td><td align="center" valign="top" charoff="50">NM_173869</td><td align="center" valign="top" char="." charoff="50">1.39</td><td align="center" valign="top" char="." charoff="50">193.70</td><td align="center" valign="top" char="." charoff="50">&#x02212;139.5</td></tr><tr><td align="left" valign="top" charoff="50">S100a9 (S100 calcium binding protein A9, or calgranulin B)</td><td align="center" valign="top" charoff="50">NM_009114</td><td align="center" valign="top" char="." charoff="50">30.74</td><td align="center" valign="top" char="." charoff="50">3973.45</td><td align="center" valign="top" char="." charoff="50">&#x02212;129.2</td></tr><tr><td align="left" valign="top" charoff="50">Stfa2 (stefin A2)</td><td align="center" valign="top" charoff="50">NM_001082545</td><td align="center" valign="top" char="." charoff="50">1.43</td><td align="center" valign="top" char="." charoff="50">174.03</td><td align="center" valign="top" char="." charoff="50">&#x02212;121.5</td></tr><tr><td align="left" valign="top" charoff="50">2810417H13Rik</td><td align="center" valign="top" charoff="50">NM_026515</td><td align="center" valign="top" char="." charoff="50">1.36</td><td align="center" valign="top" char="." charoff="50">58.47</td><td align="center" valign="top" char="." charoff="50">&#x02212;42.9</td></tr><tr><td align="left" valign="top" charoff="50">Rrm2 (ribonucleotide reductase M2)</td><td align="center" valign="top" charoff="50">NM_009104</td><td align="center" valign="top" char="." charoff="50">1.49</td><td align="center" valign="top" char="." charoff="50">59.87</td><td align="center" valign="top" char="." charoff="50">&#x02212;40.1</td></tr><tr><td align="left" valign="top" charoff="50">Birc5 (baculoviral IAP repeat- containing 5)</td><td align="center" valign="top" charoff="50">NM_009689, NM_001012273</td><td align="center" valign="top" char="." charoff="50">1.15</td><td align="center" valign="top" char="." charoff="50">42.02</td><td align="center" valign="top" char="." charoff="50">&#x02212;36.5</td></tr><tr><td align="left" valign="top" charoff="50">Ube2c (ubiquitin-conjugating enzyme E2C)</td><td align="center" valign="top" charoff="50">NM_026785</td><td align="center" valign="top" char="." charoff="50">1.50</td><td align="center" valign="top" char="." charoff="50">52.80</td><td align="center" valign="top" char="." charoff="50">&#x02212;35.2</td></tr><tr><td align="left" valign="top" charoff="50">Phgdh (3-phosphoglycerate dehydrogenase)</td><td align="center" valign="top" charoff="50">NM_016966</td><td align="center" valign="top" char="." charoff="50">1.62</td><td align="center" valign="top" char="." charoff="50">46.49</td><td align="center" valign="top" char="." charoff="50">&#x02212;28.7</td></tr><tr><td align="left" valign="top" charoff="50">Chi3l3 (chitinase-like 3)</td><td align="center" valign="top" charoff="50">NM_009892</td><td align="center" valign="top" char="." charoff="50">15.31</td><td align="center" valign="top" char="." charoff="50">424.85</td><td align="center" valign="top" char="." charoff="50">&#x02212;27.8</td></tr><tr><td align="left" valign="top" charoff="50">Top2a (topoisomerase II alpha)</td><td align="center" valign="top" charoff="50">NM_011623</td><td align="center" valign="top" char="." charoff="50">1.82</td><td align="center" valign="top" char="." charoff="50">42.86</td><td align="center" valign="top" char="." charoff="50">&#x02212;23.5</td></tr><tr><td align="left" valign="top" charoff="50">Ifitm1 (interferon induced transmembrane protein 1)</td><td align="center" valign="top" charoff="50">NM_001112715, NM_026820</td><td align="center" valign="top" char="." charoff="50">11.54</td><td align="center" valign="top" char="." charoff="50">263.59</td><td align="center" valign="top" char="." charoff="50">&#x02212;22.9</td></tr><tr><td align="left" valign="top" charoff="50">Sell (selectin, lymphocyte)</td><td align="center" valign="top" charoff="50">NM_001164059, NM_011346</td><td align="center" valign="top" char="." charoff="50">3.57</td><td align="center" valign="top" char="." charoff="50">77.47</td><td align="center" valign="top" char="." charoff="50">&#x02212;21.7</td></tr><tr><td align="left" valign="top" charoff="50">Camp (cathelicidin antimicrobial peptide)</td><td align="center" valign="top" charoff="50">NM_009921</td><td align="center" valign="top" char="." charoff="50">7.68</td><td align="center" valign="top" char="." charoff="50">160.69</td><td align="center" valign="top" char="." charoff="50">&#x02212;20.9</td></tr><tr><td align="left" valign="top" charoff="50">Plac8 (placenta-specific 8)</td><td align="center" valign="top" charoff="50">NM_139198</td><td align="center" valign="top" char="." charoff="50">58.68</td><td align="center" valign="top" char="." charoff="50">1166.53</td><td align="center" valign="top" char="." charoff="50">&#x02212;19.9</td></tr><tr><td align="left" valign="top" charoff="50">Stmn1 (stathmin 1)</td><td align="center" valign="top" charoff="50">NM_019641</td><td align="center" valign="top" char="." charoff="50">4.29</td><td align="center" valign="top" char="." charoff="50">85.24</td><td align="center" valign="top" char="." charoff="50">&#x02212;19.9</td></tr><tr><td align="left" valign="top" charoff="50">Hmgb2 (high mobility group box 2)</td><td align="center" valign="top" charoff="50">NM_008252</td><td align="center" valign="top" char="." charoff="50">5.43</td><td align="center" valign="top" char="." charoff="50">100.04</td><td align="center" valign="top" char="." charoff="50">&#x02212;18.4</td></tr><tr><td align="left" valign="top" charoff="50">Ccna2 (cyclin A2)</td><td align="center" valign="top" charoff="50">NM_009828</td><td align="center" valign="top" char="." charoff="50">1.69</td><td align="center" valign="top" char="." charoff="50">28.79</td><td align="center" valign="top" char="." charoff="50">&#x02212;17.1</td></tr><tr><td align="left" valign="top" charoff="50">Lmnb1 (lamin B1)</td><td align="center" valign="top" charoff="50">NM_010721</td><td align="center" valign="top" char="." charoff="50">2.12</td><td align="center" valign="top" char="." charoff="50">32.74</td><td align="center" valign="top" char="." charoff="50">&#x02212;15.4</td></tr><tr><td align="left" valign="top" charoff="50">Mcm7 (minichromosome maintenance deficient 7)</td><td align="center" valign="top" charoff="50">NM_008568</td><td align="center" valign="top" char="." charoff="50">1.82</td><td align="center" valign="top" char="." charoff="50">26.94</td><td align="center" valign="top" char="." charoff="50">&#x02212;14.8</td></tr><tr><td align="left" valign="top" charoff="50">Chi3l1 (chitinase-like 1)</td><td align="center" valign="top" charoff="50">NM_007695</td><td align="center" valign="top" char="." charoff="50">3.16</td><td align="center" valign="top" char="." charoff="50">45.36</td><td align="center" valign="top" char="." charoff="50">&#x02212;14.4</td></tr><tr><td align="left" valign="top" charoff="50">Uhrf1 (ubiquitin-like, containing PHD and RING finger domains, 1)</td><td align="center" valign="top" charoff="50">NM_001111078, NM_001111080, NM_001111079, NM_010931</td><td align="center" valign="top" char="." charoff="50">1.01</td><td align="center" valign="top" char="." charoff="50">13.77</td><td align="center" valign="top" char="." charoff="50">&#x02212;13.6</td></tr><tr><td align="left" valign="top" charoff="50">Gm5483 (predicted gene 5483)</td><td align="center" valign="top" charoff="50">NM_001082547</td><td align="center" valign="top" char="." charoff="50">33.08</td><td align="center" valign="top" char="." charoff="50">444.33</td><td align="center" valign="top" char="." charoff="50">&#x02212;13.4</td></tr><tr><td align="left" valign="top" charoff="50">Ly6c2 (lymphocyte antigen 6 complex, locus C2)</td><td align="center" valign="top" charoff="50">NM_001099217</td><td align="center" valign="top" char="." charoff="50">63.70</td><td align="center" valign="top" char="." charoff="50">854.05</td><td align="center" valign="top" char="." charoff="50">&#x02212;13.4</td></tr><tr><td align="left" valign="top" charoff="50">Cdca8 (cell division cycle associated 8)</td><td align="center" valign="top" charoff="50">NM_026560</td><td align="center" valign="top" char="." charoff="50">2.03</td><td align="center" valign="top" char="." charoff="50">26.12</td><td align="center" valign="top" char="." charoff="50">&#x02212;12.9</td></tr><tr><td align="left" valign="top" charoff="50">Rrm1 (ribonucleotide reductase M1)</td><td align="center" valign="top" charoff="50">NM_009103</td><td align="center" valign="top" char="." charoff="50">2.99</td><td align="center" valign="top" char="." charoff="50">35.24</td><td align="center" valign="top" char="." charoff="50">&#x02212;11.8</td></tr><tr><td align="left" valign="top" charoff="50">Mcm2 (minichromosome maintenance deficient 2)</td><td align="center" valign="top" charoff="50">NM_008564</td><td align="center" valign="top" char="." charoff="50">1.59</td><td align="center" valign="top" char="." charoff="50">18.25</td><td align="center" valign="top" char="." charoff="50">&#x02212;11.5</td></tr><tr><td align="left" valign="top" charoff="50">Ckap2l (cytoskeleton associated protein 2-like)</td><td align="center" valign="top" charoff="50">NM_181589</td><td align="center" valign="top" char="." charoff="50">1.15</td><td align="center" valign="top" char="." charoff="50">13.06</td><td align="center" valign="top" char="." charoff="50">&#x02212;11.3</td></tr><tr><td align="left" valign="top" charoff="50">Smc2 (structural maintenance of chromosomes 2)</td><td align="center" valign="top" charoff="50">NM_008017</td><td align="center" valign="top" char="." charoff="50">1.78</td><td align="center" valign="top" char="." charoff="50">19.73</td><td align="center" valign="top" char="." charoff="50">&#x02212;11.1</td></tr><tr><td align="left" valign="top" charoff="50">Fignl1 (fidgetin-like 1)</td><td align="center" valign="top" charoff="50">NM_021891, NM_001163360, NM_001163359</td><td align="center" valign="top" char="." charoff="50">1.05</td><td align="center" valign="top" char="." charoff="50">11.65</td><td align="center" valign="top" char="." charoff="50">&#x02212;11.1</td></tr><tr><td align="left" valign="top" charoff="50">Tacc3 (transforming, acidic coiled-coil containing protein 3)</td><td align="center" valign="top" charoff="50">NM_001040435</td><td align="center" valign="top" char="." charoff="50">2.22</td><td align="center" valign="top" char="." charoff="50">23.91</td><td align="center" valign="top" char="." charoff="50">&#x02212;10.8</td></tr><tr><td align="left" valign="top" charoff="50">Mcm5 (minichromosome maintenance deficient 5)</td><td align="center" valign="top" charoff="50">NM_008566</td><td align="center" valign="top" char="." charoff="50">2.27</td><td align="center" valign="top" char="." charoff="50">23.49</td><td align="center" valign="top" char="." charoff="50">&#x02212;10.4</td></tr><tr><td align="left" valign="top" charoff="50">Cdk1 (cyclin-dependent kinase 1)</td><td align="center" valign="top" charoff="50">NM_007659</td><td align="center" valign="top" char="." charoff="50">2.51</td><td align="center" valign="top" char="." charoff="50">25.52</td><td align="center" valign="top" char="." charoff="50">&#x02212;10.2</td></tr><tr><td align="left" valign="top" charoff="50">Hmgn2 (high mobility group nucleosomal binding domain 2)</td><td align="center" valign="top" charoff="50">NM_016957</td><td align="center" valign="top" char="." charoff="50">30.41</td><td align="center" valign="top" char="." charoff="50">291.25</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.6</td></tr><tr><td align="left" valign="top" charoff="50">Serpinb1a (serine peptidase inhibitor, clade B, member 1a)</td><td align="center" valign="top" charoff="50">NM_025429</td><td align="center" valign="top" char="." charoff="50">2.27</td><td align="center" valign="top" char="." charoff="50">20.99</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.2</td></tr><tr><td align="left" valign="top" charoff="50">Rfc4 (replication factor C4)</td><td align="center" valign="top" charoff="50">NM_145480</td><td align="center" valign="top" char="." charoff="50">1.05</td><td align="center" valign="top" char="." charoff="50">9.48</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.0</td></tr><tr><td align="left" valign="top" charoff="50">Igfbp4 (insulin-like growth factor binding protein 4)</td><td align="center" valign="top" charoff="50">NM_010517</td><td align="center" valign="top" char="." charoff="50">3.47</td><td align="center" valign="top" char="." charoff="50">31.14</td><td align="center" valign="top" char="." charoff="50">&#x02212;9.0</td></tr><tr><td align="left" valign="top" charoff="50">Ly6c1 (lymphocyte antigen 6 complex, locus C1)</td><td align="center" valign="top" charoff="50">NM_010741, NM_001252058, NM_001252055, NM_001252057, NM_001252056</td><td align="center" valign="top" char="." charoff="50">1.88</td><td align="center" valign="top" char="." charoff="50">16.49</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.8</td></tr><tr><td align="left" valign="top" charoff="50">Rab27a (RAB27A, member RAS oncogene family)</td><td align="center" valign="top" charoff="50">NM_023635</td><td align="center" valign="top" char="." charoff="50">1.35</td><td align="center" valign="top" char="." charoff="50">11.57</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.6</td></tr><tr><td align="left" valign="top" charoff="50">Gmnn (geminin)</td><td align="center" valign="top" charoff="50">NM_020567</td><td align="center" valign="top" char="." charoff="50">3.27</td><td align="center" valign="top" char="." charoff="50">27.03</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.3</td></tr><tr><td align="left" valign="top" charoff="50">Gm5416 (predicted gene 5416)</td><td align="center" valign="top" charoff="50">NM_001082542</td><td align="center" valign="top" char="." charoff="50">9.72</td><td align="center" valign="top" char="." charoff="50">79.34</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.2</td></tr><tr><td align="left" valign="top" charoff="50">Cks1b (CDC28 protein kinase 1b)</td><td align="center" valign="top" charoff="50">NM_016904</td><td align="center" valign="top" char="." charoff="50">5.61</td><td align="center" valign="top" char="." charoff="50">45.08</td><td align="center" valign="top" char="." charoff="50">&#x02212;8.0</td></tr><tr><td align="left" valign="top" charoff="50">Ltb4r1 (leukotriene B4 receptor 1)</td><td align="center" valign="top" charoff="50">NM_008519</td><td align="center" valign="top" char="." charoff="50">1.24</td><td align="center" valign="top" char="." charoff="50">9.80</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.9</td></tr><tr><td align="left" valign="top" charoff="50">Mcm3 (minichromosome maintenance deficient 3)</td><td align="center" valign="top" charoff="50">NM_008563</td><td align="center" valign="top" char="." charoff="50">4.20</td><td align="center" valign="top" char="." charoff="50">33.30</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.9</td></tr><tr><td align="left" valign="top" charoff="50">Lbr (lamin B receptor)</td><td align="center" valign="top" charoff="50">NM_133815</td><td align="center" valign="top" char="." charoff="50">1.89</td><td align="center" valign="top" char="." charoff="50">14.78</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.8</td></tr><tr><td align="left" valign="top" charoff="50">Myc (myelocytomatosis oncogene)</td><td align="center" valign="top" charoff="50">NM_001177354, NM_001177352, NM_001177353, NM_010849</td><td align="center" valign="top" char="." charoff="50">1.88</td><td align="center" valign="top" char="." charoff="50">14.08</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.5</td></tr><tr><td align="left" valign="top" charoff="50">Tpx2 (TPX2, microtubule-associated protein homolog)</td><td align="center" valign="top" charoff="50">NM_001141977, NM_001141976, NM_001141975, NM_028109, NM_001141978</td><td align="center" valign="top" char="." charoff="50">2.51</td><td align="center" valign="top" char="." charoff="50">18.81</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.5</td></tr><tr><td align="left" valign="top" charoff="50">Mcm4 (minichromosome maintenance deficient 4)</td><td align="center" valign="top" charoff="50">NM_008565</td><td align="center" valign="top" char="." charoff="50">2.52</td><td align="center" valign="top" char="." charoff="50">18.65</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.4</td></tr><tr><td align="left" valign="top" charoff="50">Tipin (timeless interacting protein)</td><td align="center" valign="top" charoff="50">NM_025372</td><td align="center" valign="top" char="." charoff="50">3.01</td><td align="center" valign="top" char="." charoff="50">21.31</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.1</td></tr><tr><td align="left" valign="top" charoff="50">Asf1b (anti-silencing function 1B histone chaperone)</td><td align="center" valign="top" charoff="50">NM_024184</td><td align="center" valign="top" char="." charoff="50">2.07</td><td align="center" valign="top" char="." charoff="50">14.57</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.1</td></tr><tr><td align="left" valign="top" charoff="50">Gpr97 (G protein-coupled receptor 97)</td><td align="center" valign="top" charoff="50">NM_173036</td><td align="center" valign="top" char="." charoff="50">1.06</td><td align="center" valign="top" char="." charoff="50">7.45</td><td align="center" valign="top" char="." charoff="50">&#x02212;7.0</td></tr><tr><td align="left" valign="top" charoff="50">Lig1 (ligase I, DNA, ATP- dependent)</td><td align="center" valign="top" charoff="50">NM_001199310, NM_010715, NM_001083188</td><td align="center" valign="top" char="." charoff="50">2.38</td><td align="center" valign="top" char="." charoff="50">16.43</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.9</td></tr><tr><td align="left" valign="top" charoff="50">Il18rap (interleukin 18 receptor accessory protein)</td><td align="center" valign="top" charoff="50">NM_010553</td><td align="center" valign="top" char="." charoff="50">1.29</td><td align="center" valign="top" char="." charoff="50">8.70</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.8</td></tr><tr><td align="left" valign="top" charoff="50">Gins1 (GINS complex subunit 1 (Psf1 homolog))</td><td align="center" valign="top" charoff="50">NM_001163476,NM_027014</td><td align="center" valign="top" char="." charoff="50">1.43</td><td align="center" valign="top" char="." charoff="50">9.62</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.8</td></tr><tr><td align="left" valign="top" charoff="50">Tuba8 tubulin, alpha 8</td><td align="center" valign="top" charoff="50">NM_017379</td><td align="center" valign="top" char="." charoff="50">2.24</td><td align="center" valign="top" char="." charoff="50">14.99</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.7</td></tr><tr><td align="left" valign="top" charoff="50">Trip13 (thyroid hormone receptor interactor 13)</td><td align="center" valign="top" charoff="50">NM_027182</td><td align="center" valign="top" char="." charoff="50">1.74</td><td align="center" valign="top" char="." charoff="50">11.61</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.7</td></tr><tr><td align="left" valign="top" charoff="50">Lsm5 (LSM5 homolog, U6 small nuclear RNA associated)</td><td align="center" valign="top" charoff="50">NM_025520</td><td align="center" valign="top" char="." charoff="50">7.97</td><td align="center" valign="top" char="." charoff="50">52.46</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.6</td></tr><tr><td align="left" valign="top" charoff="50">Atad2 (ATPase family, AAA domain containing 2)</td><td align="center" valign="top" charoff="50">NM_027435</td><td align="center" valign="top" char="." charoff="50">2.05</td><td align="center" valign="top" char="." charoff="50">13.01</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.4</td></tr><tr><td align="left" valign="top" charoff="50">Syce2 (synaptonemal complex central element protein 2)</td><td align="center" valign="top" charoff="50">NM_001168244, NM_027954, NM_001168246, NR_031759</td><td align="center" valign="top" char="." charoff="50">2.90</td><td align="center" valign="top" char="." charoff="50">18.04</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.2</td></tr><tr><td align="left" valign="top" charoff="50">Dkc1 (dyskeratosis congenita 1, dyskerin</td><td align="center" valign="top" charoff="50">NM_001030307</td><td align="center" valign="top" char="." charoff="50">1.28</td><td align="center" valign="top" char="." charoff="50">7.96</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.2</td></tr><tr><td align="left" valign="top" charoff="50">Hsh2d (hematopoietic SH2 domain containing)</td><td align="center" valign="top" charoff="50">NM_197944</td><td align="center" valign="top" char="." charoff="50">1.85</td><td align="center" valign="top" char="." charoff="50">11.31</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.1</td></tr><tr><td align="left" valign="top" charoff="50">Haus4 (HAUS augmin-like complex, subunit 4)</td><td align="center" valign="top" charoff="50">NM_145462</td><td align="center" valign="top" char="." charoff="50">1.16</td><td align="center" valign="top" char="." charoff="50">6.96</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.0</td></tr><tr><td align="left" valign="top" charoff="50">S100a8 (S100 calcium binding protein A8 (calgranulin A)</td><td align="center" valign="top" charoff="50">NM_013650</td><td align="center" valign="top" char="." charoff="50">799.33</td><td align="center" valign="top" char="." charoff="50">4789.38</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.0</td></tr><tr><td align="left" valign="top" charoff="50">Cenpv (centromere protein V)</td><td align="center" valign="top" charoff="50">NM_028448</td><td align="center" valign="top" char="." charoff="50">1.14</td><td align="center" valign="top" char="." charoff="50">6.83</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.0</td></tr><tr><td align="left" valign="top" charoff="50">Arhgap15 (Rho GTPase activating protein 15)</td><td align="center" valign="top" charoff="50">NM_153820, NM_001025377</td><td align="center" valign="top" char="." charoff="50">1.76</td><td align="center" valign="top" char="." charoff="50">10.52</td><td align="center" valign="top" char="." charoff="50">&#x02212;6.0</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Differentially expressed genes in WT vs NOD2 KO macrophages treated with MDP and LPS. Criteria for selection of genes are the same as described in <xref ref-type="table" rid="t1">Table 1</xref>. Positive values represent expression ratios of WT/KO whereas negative values represent KO/WT ratios. Criteria for selection of genes: minimum expression level: 1; minimum fold change: 6.0, which is the threshold level that can be reliably corroborated by real time RT-PCR. Positive values represent expression ratios of WT/KO whereas negative values represent KO/WT ratios.</p></fn></table-wrap-foot></table-wrap></floats-group></article>